
Molecular Cell

Unique Structural Features of the Mitochondrial AAA+ Protease AFG3L2 Reveal the Molecular Basis for Activity in Health and Disease

Graphical Abstract



Authors

Cristina Puchades, Bojian Ding, Albert Song, R. Luke Wiseman, Gabriel C. Lander, Steven E. Glynn

Correspondence

glander@scripps.edu (G.C.L.), steven.glynn@stonybrook.edu (S.E.G.)

In Brief

The AFG3L2 protease maintains protein quality control in mitochondria. Puchades et al. report a cryo-EM structure of AFG3L2 that reveals how structural adaptations are used to pull substrates into a degradation chamber. Neurodegenerative disease-relevant mutations cluster to these unique features and alter the activity and stability of the protease.

Highlights

- Substrate-bound structure of the mitochondrial AFG3L2 protease catalytic core
- AFG3L2 evolved adaptations to promote a distinct mode of substrate handling
- Specific structural features contact the substrate and stabilize the protease complex
- Neurodegenerative disease mutations cluster to unique AFG3L2 structural elements

Puchades et al., 2019, Molecular Cell 75, 1073–1085 September 5, 2019 © 2019 Elsevier Inc. https://doi.org/10.1016/j.molcel.2019.06.016



Unique Structural Features of the Mitochondrial AAA+ Protease AFG3L2 Reveal the Molecular Basis for Activity in Health and Disease

Cristina Puchades,^{1,2,3,5} Bojian Ding,^{4,5} Albert Song,^{1,2,3} R. Luke Wiseman,² Gabriel C. Lander,^{1,*} and Steven E. Glynn^{4,6,*} ¹Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

²Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA

³Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA

⁴Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794, USA

⁵These authors contributed equally

*Correspondence: glander@scripps.edu (G.C.L.), steven.glynn@stonybrook.edu (S.E.G.) https://doi.org/10.1016/j.molcel.2019.06.016

SUMMARY

Mitochondrial AAA+ guality-control proteases regulate diverse aspects of mitochondrial biology through specialized protein degradation, but the underlying mechanisms of these enzymes remain poorly defined. The mitochondrial AAA+ protease AFG3L2 is of particular interest, as genetic mutations localized throughout AFG3L2 are linked to diverse neurodegenerative disorders. However, a lack of structural data has limited our understanding of how mutations impact enzymatic function. Here, we used cryoelectron microscopy (cryo-EM) to determine a substrate-bound structure of the catalytic core of human AFG3L2. This structure identifies multiple specialized structural features that integrate with conserved motifs required for ATP-dependent translocation to unfold and degrade targeted proteins. Many disease-relevant mutations localize to these unique structural features of AFG3L2 and distinctly influence its activity and stability. Our results provide a molecular basis for neurological phenotypes associated with different AFG3L2 mutations and establish a structural framework to understand how different members of the AAA+ superfamily achieve specialized biological functions.

INTRODUCTION

Protein quality control is central to cellular function and survival in all living organisms (Chen et al., 2011). Maintaining protein quality control relies on a complex network of ATP-dependent proteases that regulate protein homeostasis (Bohovych et al., 2015). The membrane-anchored AAA+ protease FtsH is essential for growth in *E. coli* and is conserved across all kingdoms of life (Langklotz et al., 2012). These FtsH-related proteins specialize in protein quality control in membranous environments and are found in

eukaryotic mitochondrial and chloroplastic membranes, functioning as hexameric, ATP-driven protein quality-control systems that process membrane-embedded and associated protein substrates (Leonhard et al., 1996; Wagner et al., 2012). All FtsH-related AAA+ proteases are characterized by a shared topology comprising an N-terminal domain, a transmembrane region, an AAA+ ATPase domain, and a zinc-metalloprotease domain (Janska et al., 2013; Sauer and Baker, 2011). Notably, mitochondria contain two types of FtsH-related AAA+ proteases, referred to as m- and i-AAA proteases, which are tethered to the mitochondrial inner membrane (IM) but expose their enzymatic domains to the matrix and intermembrane spaces (IMS), respectively (Figure 1A; Leonhard et al., 1996).

We previously solved a cryoelectron microscopy (cryo-EM) structure of the yeast i-AAA YME1, which revealed how a sequential ATP hydrolysis cycle drives hand-over-hand translocation of substrate through the central pore of the hexamer (Puchades et al., 2017). Given the strong structural commonalities shared by all FtsH-related AAA+ proteases, the basic translocation mechanism we described in YME1 is likely to be conserved from bacteria to humans. However, despite this conserved mechanism, FtsH-related proteins have each evolved the ability to recognize and degrade distinct substrates within unique cellular environments, giving rise to this family's modulation of diverse biological pathways (Bittner et al., 2017; Glynn, 2017; Nishimura et al., 2016). While their individual substrate specificities likely involve the integration of specialized mechanisms to recognize, recruit, engage, and degrade protein targets, the molecular basis for this specialization remains poorly understood.

The human m-AAA protease assembles as homohexamers of AFG3L2 subunits or heterohexamers comprising AFG3L2 subunits and subunits of the closely related homolog paraplegin (SPG7) (Banfi et al., 1999; Koppen et al., 2007). AFG3L2-containing complexes regulate important biological functions, including mitochondrial ribosome assembly, the expression, maturation, and degradation of electron transport chain complexes, supervision of mitochondrial dynamics, and the regulation of calcium homeostasis (Arlt et al., 1998; Consolato et al., 2018; König et al., 2016; Nolden et al., 2005). Furthermore, m-AAA proteases are essential for axonal development in mammals, and loss or

⁶Lead Contact




Figure 1. Structure of Substrate-Bound AFG3L2 Reveals Four Distinct Mutational Hotspots Linked to Disease

(A) Cartoon representation of i- and m-AAA proteases in the mitochondrial inner membrane with the ATPase domains of AFG3L2 colored gray and the zinc metalloprotease shown in yellow.

(B) Schematic representation of the AFG3L2 constructs used in this study.

(C) The atomic model of an AFG3L2 protomer with the ATPase and protease domains colored gray and yellow, respectively. Each residue associated with disease is shown as a sphere colored green, pink, purple, or yellow in accordance with the mutational hotspots identified in our structure. Substrate (orange) interacts with pore-loops 1 (cyan) and 2 (green) of the ATPases and the active site of the protease. The N and C termini of the catalytic core are colored blue and red, respectively. (D) Cutaway side-view of the AFG3L2 homohexamer showing the substrate (orange) in both the ATPase central pore and the proteolytic active sites. Residues linked to disease are shown as spheres colored as in (C).

(E) Top view of the ATPase domains with disease-related residues depicted as green spheres, demonstrating their proximity to nucleotide (pink) at the intersubunit interface. The two ATPase domains that were rigid body fit into the density are represented as a thin ribbon.

(F) Axial view of the protease ring shows that SCA28 mutations (pink and purple spheres) localize to the intersubunit interfaces and recessively inherited mutations (yellow spheres) are found in close proximity to the proteolytic active site.

reduction of wild type AFG3L2 lead to pleiotropic phenotypes, such as mitochondrial transport defects, mitochondrial fragmentation, and reductions in both mitochondrial membrane potential and respiration (Almajan et al., 2012; Kondadi et al., 2014; Levytskyy et al., 2016; Maltecca et al., 2008, 2009; Mancini et al., 2019). In fact, point mutations localized throughout *AFG3L2*

are linked to multiple neurodegenerative disorders in humans that present with diverse pathologies and severity. The majority of identified AFG3L2 mutations are implicated in the autosomal dominant disease spinocerebellar ataxia type 28 (SCA28) (Cagnoli et al., 2006; Di Bella et al., 2010; Edener et al., 2010; Löbbe et al., 2014; Mariotti et al., 2008; Svenstrup et al., 2017; Szpisjak et al., 2017; Zühlke et al., 2015). An alternative heterozygous AFG3L2 point mutation has been causatively linked to dominant optic atrophy (DOA), whereas homozygous individuals carrying rare mutations in AFG3L2 present neurodegenerative phenotypes distinct from either DOA or SCA28 (Table S1; Charif et al., 2015; Colavito et al., 2017; Eskandrani et al., 2017; Pierson et al., 2011). The genetic relationship between diverse AFG3L2 mutations and distinct disease severity and neurodegenerative pathologies indicates that these mutations differentially impact m-AAA protease activity. Despite this relationship, a lack of structural information has limited our understanding of the molecular mechanisms linking specific mutations to altered enzymatic activity and ultimately pathology.

Here, we present an atomic model of the human AFG3L2 homohexameric m-AAA protease trapped in the act of processing substrate, revealing the network of molecular interactions responsible for substrate engagement, unfolding, transfer across the proteolytic chamber, and proteolysis. While this structure confirms that the fundamental mechanism relating ATP hydrolysis to substrate translocation is conserved between i-AAA and m-AAA, this study also reveals how AFG3L2 has evolved unique structural features for processing substrates located within or in proximity to the matrix-facing surface of the IM. Further, our structure defines how disease-relevant mutations implicated in AFG3L2-associated neurodegenerative disorders distinctly impact the mechanism of this AAA+ protease. Thus, our structure-function studies not only provide a much-needed structural framework to understand how different AAA+ proteases build upon a common mechanistic core to process specific substrates, but also reveal a molecular basis to define the distinct neuropathologies associated with different AFG3L2 mutations.

RESULTS

Structure of the Human Substrate-Bound AFG3L2 Catalytic Core

We solved a ~3.1 Å resolution cryo-EM structure of a truncated construct of AFG3L2 comprising the ATPase and protease domains (residues 272-797; coreAFG3L2) (Figures 1 and S1). The construct was stabilized for structural analysis by incorporating ATPase-inactivating Walker B (WB, E408Q) and protease-inactivating (PI, E575Q) mutations and vitrified in the presence of saturating concentrations of the non-hydrolyzable ATP analog AMP-PNP. The resulting reconstruction was of sufficient quality to build an atomic model of the six protease domains and four of the six ATPase domains (Figures 1 and S1). The atomic models of the large and small ATPase subdomains of one of the wellresolved subunits were independently rigid-body fit into the low resolution cryo-EM density of the remaining two ATPase domains to generate a backbone trace in these regions, completing an atomic model of the entire homohexameric AFG3L2 complex (Figures 1 and S2; Table S2).

Our reconstruction shows that AFG3L2 assembles into two stacked rings with a planar C6 symmetric protease base topped by an asymmetric ATPase spiral (Figures 1D–1F) – a quaternary structure similar to that observed for substrate-bound YME1 (Figure S2A; Puchades et al., 2017). The three upper subunits of the AFG3L2 staircase are bound to AMP-PNP (termed ATP2-ATP4 for simplicity), while the lowermost subunit is bound to ADP (Figure S2). The limited resolution of the remaining two subunits did not allow for unambiguous identification of nucleotide state, although the positioning of these subunits within the staircase correspond to the nucleotide-free (apo) "step"-subunit and the uppermost ATP-bound subunit (ATP1) within YME1 (Figure S2A). While we could not experimentally verify the identity of the nucleotide in these subunits, we previously showed that nucleotide state allosterically determines the rigid body domain rotations of the ATPases and consequently their position within the staircase. We therefore refer to these subunits as apo and ATP1 (Figure S2A). Importantly, we observe density corresponding to substrate peptide threaded through the center of the ATPase spiral of AFG3L2, as has been observed for other AAA+ proteins (de la Peña et al., 2018; Gates et al., 2017; Monroe et al., 2017; Puchades et al., 2017; Ripstein et al., 2017; Yu et al., 2018). Unexpectedly, this translocating substrate density directly contacts the center of the protease ring. Furthermore, use of the protease inactivating E575Q mutation resulted in observable density corresponding to substrate trapped in the proteolytic active sites of the ATP2-4 subunits (Figures 1C and 1F).

Modulation of a Conserved Translocation Mechanism by AFG3L2-Specific Pore-Loop 1 Residues

Numerous structures of substrate-bound AAA+ unfoldases have been solved by cryo-EM and suggest a conserved substrate translocation mechanism wherein a sequential ATP hydrolysis cycle powers a hand-over-hand conveyance of unfolded polypeptide through the central channel of the hexamer (de la Peña et al., 2018; Gates et al., 2017; Monroe et al., 2017; Puchades et al., 2017; Ripstein et al., 2017; Yu et al., 2018). Like in other AAA+ ATPases, an aromatic residue within the ATPase domain pore-loop 1 of AFG3L2 (F381) forms a spiral staircase around the translocating substrate and intercalates into its backbone (Figures 2A, 2C, S2B, and S2C). To verify the key role of F381 in substrate translocation, we monitored ATP hydrolysis and substrate degradation for an engineered hexameric AFG3L2 (^{cchex}AFG3L2), where the transmembrane domains were substituted by a coiled coil that ensures hexamerization of active subunits in the absence of stabilizing mutations (Figure 1B; Ding et al., 2018; Rampello and Glynn, 2017; Shi et al., 2016). Incorporation of an F381A substitution abolished substrate degradation, while only mildly impacting ATP hydrolysis (Figure 2B), confirming a conserved role for the aromatic pore-loop 1 residue in substrate handling.

A requirement for the hand-over-hand translocation mechanism is allosteric transmission of nucleotide state to the pore-loops. This allostery was described in YME1, wherein an Asp-Gly-Phe motif located at the interface between neighboring ATPases alternates conformations between a compact α -helix and an extended loop that spans the nucleotide-binding pocket




Figure 2. Unique Features of AFG3L2 Mediate Substrate Transfer from the ATPase to the Protease

(A) The ATPase domain's N terminus (top, blue), pore-loop 1 (middle, cyan), and pore-loop 2 (bottom, green) directly contact the substrate polypeptide (cryo-EM density shown as mesh). Nucleotide bound to the adjacent subunit is shown (pink), highlighting the position of the disease-associated residues R468 and N432 relative to the neighboring subunit's nucleotide-binding pocket.

(B) ATPase and substrate degradation rates for ^{cchex}AFG3L2 and its variants with single-point substitutions in pore-loops 1, 2, and the central protrusion validate the functional relevance of these regions for substrate processing. Values are means of independent replicates ($n \ge 3$) ± SD. ** $p \le 0.001$, *** $p \le 0.001$, *** $p \le 0.001$, as calculated using Student's two-tailed t test and statistical significances are shown relative to wild type (WT) ^{cchex}AFG3L2.

(C) The pore-loop 1 spiral staircase with residues F381 and M380 illustrated as sticks and the cryo-EM density shown as a gray mesh. M380 interacts with F381 of the adjacent subunit, forming a continuous network that surrounds the substrate (orange).

(D) Cutaway view of the AFG3L2 homohexamer cryo-EM reconstruction shows that the pore-loop 2 of the lowest subunit (green) contacts the central protrusion (purple). Unsharpened density for the substrate is shown in orange, demonstrating contacts with both pore-loop 2 and the central protrusion.

(E) Ribbon representation of the substrate (orange) in the central pore, with pore-loops 1 and 2 colored blue and green, respectively, to highlight the two staircases that simultaneously interact with the substrate. The lowest pore-loop 2 directly contacts the central protrusion, shown in purple.

(F) Detailed view of the staircase formed by residues F421 from pore-loop 2 (green) and contact with the central protrusion (purple). Substrate is orange, and cryo-EM density is shown as a mesh.

at the inter-protomer interface (Puchades et al., 2017). Conformational switching of this region, termed the inter-subunit signaling (ISS) motif, is directly controlled by nucleotide state, which in turn defines the positions of pore-loops 1 and 2 (Augustin et al., 2009; Puchades et al., 2017). Together, this gives rise to a mechanism wherein the pore loops of ATP-bound subunits engage the substrate, ATP hydrolysis in the lowermost subunit causes its pore loops to detach from the substrate, and nucleotide exchange enables re-engagement of substrate at the top of the staircase. The correlation between nucleotide state, conformation of the ISS, and positioning of the pore loops is conserved in our AFG3L2 structure, indicating that allosteric regulation of pore-loop conformation in response to nucleotide state, and thereby the fundamental mechanism of substrate translocation, is conserved between i- and m-AAA proteases across eukaryotes (Figures S2B and S2C).

Despite conservation of the overall mechanism, the poreloops of AFG3L2 contain structural features distinct from those observed in YME1 or other AAA+ ATPases, which modulate substrate translocation. The methionine residue (M380) immediately

preceding the pore-loop 1 aromatic (F381) contacts F381 of the counterclockwise adjacent subunit to form a continuous chain of residues that wrap around the substrate in the central channel (Figure 2C). This methionine is largely conserved in FtsH-related enzymes, with the notable exception of YME1 (Figure S3A). An M380V mutation, which converts this methionine to the corresponding valine in YME1, increased ATP hydrolysis while moderately decreasing substrate degradation indicating reduced enzymatic efficiency (Figure 2B). Importantly, in most classical AAA+ proteins, including Vps4, the NDB1 domain of HSP104, as well as five of the six ATPase subunits of the 26S proteasome, this residue corresponds to a lysine that forms π cation interactions with the aromatic residues of both cis and trans loops (de la Peña et al., 2018; Gates et al., 2017; Monroe et al., 2017). In AFG3L2, the methionine cannot engage in π -cation interactions with the aromatic staircase and instead is limited to steric hindrance and weak van der Waals forces. Replacing this methionine with a lysine (M380K) completely abolished AFG3L2 activity (Figure 2B), consistent with corresponding Met to Lys mutations in the AFG3L2 homologs Yta10

and Yta12 that obliterated substrate processing in yeast (Tatsuta et al., 2007). Together, these data show that the residue immediately prior to the pore-loop 1 aromatic gives rise to a distinct configuration of the central channel that specifically influences substrate translocation in different AAA+ proteins.

Pore-Loop 2 Coordinates Substrate Transfer to a Central Protrusion within the Protease Domain

Pore-loop 2 is the least conserved region of the ATPase domain across FtsH-related proteases. Surprisingly, we observe that a four-residue insertion in pore-loop 2 of AFG3L2 positions the central aromatic residue F421 closer to the substrate than observed for YME1 (Puchades et al., 2017), creating a second spiral staircase that engages the substrate—an interaction not observed in any other substrate-bound AAA+ ATPase solved to date. Incorporation of an F421A substitution in ^{cchex}AFG3L2 impaired substrate degradation with no impact on ATPase activity (Figure 2B). These additional contacts with the translocating substrate likely increase the ATPase's "grip" on substrate for optimal processing of AFG3L2-specific substrates.

Importantly, the extended AFG3L2 pore-loop 2 positions F421 of the two lowest spiral subunits (ATP4 and ADP) (Figures 2E and 2F) deep in the interior of the proteolytic cavity. In this configuration, F421 of the ADP subunit's pore-loop 2 contacts a "central protrusion" within the protease domain. This protrusion is formed by residues 673-695 of each subunit, which form a hexamer of six upward-projecting loops at the central base of the protease ring, directed toward the incoming translocating substrate (Figures 2D and 2E). Six M683 residues crown the top of the central protrusion, and F421 from the lowermost pore-loop 2 directly contacts the nearest M683 in a manner reminiscent of the Phe-Met interactions observed in the pore-loop 1 spiral (Figures 2D-2F). Moreover, at low sigma values the density corresponding to translocating substrate extends beyond the lowermost F421 and in close proximity to the M683 crown (Figure 2D). Incorporation of an M683A substitution into cchex-AFG3L2 moderately reduced substrate degradation while minimally affecting ATP hydrolysis, mirroring the impact of the F421A mutation (Figure 2B). We thus conclude that the organization of the extended pore-loop 2 and the central protease loops in AFG3L2 likely plays an important role in facilitating substrate transfer from the ATPase spiral to the proteolytic ring.

The N Terminus of the AFG3L2 ATPase Domain Mediates Membrane-Proximal Interactions with the Substrate

Our structure also reveals a previously undescribed organization of the ATPase domain's N terminus. This N terminus connects the catalytic core of AFG3L2 to the transmembrane domains and begins with a flexible glycine-rich region (residues 272–287). Despite this region being present in our ^{core}AFG3L2 construct, it was not observed in our cryo-EM reconstruction (Figure S3A). However, the residues immediately following this region (residues 288–295) form an additional spiral staircase above the ATPase domains that surrounds and contacts the translocating substrate (blue in Figure 3A). Deleting the ordered, substrate-interacting ATPase N terminus in ^{cchex}AFG3L2 (residues 272–295) significantly impaired substrate degradation

without impacting hydrolysis, whereas deletion of just the flexible Gly-rich linker region (residues 272–281) did not influence either activity. While the resolution of our reconstruction in this region is insufficient to determine the precise nature of the interactions with the substrate, the position of the backbone chain indicates that L288 and F289 are in the immediate vicinity of the substrate. Accordingly, an F289A substitution reduced the rate of protein degradation by ~30% with no significant alteration in ATPase rate (Figure 3D). Based on these findings, we speculate that the N termini might form an additional, substrate-intercalating staircase, closely mirroring the organization of the pore loops 1 and 2.

After leaving the site of substrate interaction near the central channel, each N terminus snakes across the interface between neighboring ATPases, directly above the intersubunit interface where the ISS motif engages the counter-clockwise adjacent subunit (Figures 3B and 3C). Interestingly, L299 of each N terminus inserts into a hydrophobic groove formed by the trans packing of the ISS motif against each ATP-bound subunit (Figure 3C). In the ADP-bound subunit, for which there are no ISS interactions and thus the hydrophobic groove is absent, L299 is repositioned closer to the ISS of the cis subunit. The maintenance of these interactions regardless of nucleotide state suggested that the packing of L299 against the ATPase body may stabilize the N terminus and promote interaction with substrate. As predicted, cchexAFG3L2 containing L299A shows 50% reduction in substrate degradation without impacting ATP hydrolysis (Figure 3D). Taken together, this reveals an unanticipated role for the AFG3L2 ATPase N terminus in mediating contacts with the substrate that are important for engagement and translocation.

The AFG3L2 C Terminus Encircles the Hexamer to Adopt a Membrane-Proximal Position

Our construct contained the complete AFG3L2 C terminus, comprising residues 750-797-a region that is highly variable among FtsH-related AAA+ proteases and, in AFG3L2, contains a number of charged residues at the far C terminus (Figure S3B). While we do not observe density for the charged C-terminal tail in the structure (residues 780-797), well-defined density is present for the residues immediately preceding the tail (residues 750-779) in the three AMP-PNP bound subunits (ATP2-ATP4) (Figure 3A). Unexpectedly, this ordered C terminus extends upward from the base of the protease domain along the exterior surface of the complex to interact with both the protease and the ATPase domains of the cis subunit and the interdomain linker of the counterclockwise adjacent subunit. This arrangement of the C terminus would position the highly charged tail at the membrane-proximal face of AFG3L2. Truncation of the C terminus at residue 750 in the ^{core}AFG3L2^{WB/PI} construct, which is not stabilized by the hexamerizing coiled coil, decreased recovery of AFG3L2 hexamers as measured by size exclusion chromatography (SEC) (Figure S4A). In contrast, removal of the unobserved charged tail alone (residues 781-797) did not impact complex recovery. This indicates that the interaction of the C-terminal residues 750-779 across neighboring ATPase domains is important for stabilization and assembly of the active hexamer. Consistent with this, deletion of residues 750–797 in ^{cchex}AFG3L2 reduced both ATPase activity and substrate degradation, whereas




Figure 3. The N and C Termini of the Catalytic Core of AFG3L2 Play an Essential Structural Role at the Membrane-Proximal Region

(A) Atomic model of the AFG3L2 catalytic core shown as a ribbon with the cryo-EM density of the N and C termini shown in blue and red, respectively. The N termini of the ATPase domains extend across the nucleotide-binding pocket (nucleotides as pink spheres) and form a spiral staircase around the substrate (orange). The C termini extend across the outer surface of the complex.

(B) Top view of the ATPase staircase shows how the N termini cross over the nucleotide-binding pocket at the inter-subunit interface and contact the substrate.

(C) Close-up of the interaction network in the AMPPNP-bound nucleotide-binding pocket: (1) the Arg-fingers (R465 and R468) of the neighboring subunit (white) contact the nucleotide; (2) F369 interacts with F441 of the ISS motif (dark green) of the neighboring subunit; (3) the N-terminal L299 is positioned above these two F residues; and (4) M321 and K328 in the N terminus of the ATPase domain interact with W779 in the C terminus of the protease domain. The two ATPase domains that were rigid body fit into the density are represented as a thin ribbon.

(D) ATPase and substrate degradation rates for $^{\rm cchex}{\sf AFG3L2}$ and its variants with truncations or single-point substitutions in the N and C termini reveal that the ordered residues in these regions are important for activity. Single-point mutations in F289 and L299 in the N terminus as well as W779 in the C terminus highlight the functional relevance of the interactions mediated by these residues. Values are means of independent replicates (n \geq 3) \pm SD. ***p \leq 0.001, ****p \leq 0.001 as calculated using Student's two-tailed t test and statistical significances.

deletion of residues 781–797 had no significant effect on either activity. The final C-terminal residue for which we observe well-ordered density is W779, which is sandwiched between M321 and K328 at the membrane-proximal surface of the ATPase domain (Figure 3C). These stabilizing sulfur-aromatic and cation- π interactions likely secure W779 in position, anchoring the base of the charged C-terminal tail for potential substrate interaction. In support of this, incorporating a W779R substitution into ^{cchex}AFG3L2 impaired substrate degradation without impacting ATP hydrolysis (Figure 3D). This reveals an important role for the C terminus in dictating complex stability and shows that interactions driven by the organization of C-terminal residues influence important aspects of AFG3L2 substrate processing.

Disease-Relevant AFG3L2 Mutations Localize to Four "Hotspots" on the AFG3L2 Structure

We next sought to evaluate how specific disease-relevant AFG3L2 mutations impact its activity. Mapping disease-relevant AFG3L2 mutations onto our structure reveals that all mutations

localize to four "hotspots" within the hexameric complex (Figures 1C–1F). Intriguingly, all of the autosomal dominant mutations localize to intersubunit interfaces of the hexamer, including (1) the lateral interface between adjacent ATPase subunits where the nucleotide binding pocket is formed, (2) the tightly interconnected helices that dominate the lateral interface of the protease domain, and (3) the central protrusion of the AFG3L2 protease ring that is involved in substrate transfer to the protease domains. In contrast, recessive mutations localize near the protease active sites in the periphery of the protease ring. The clustering of these mutations into distinct regions in the structure suggests distinct effects on AFG3L2 activity.

Disease Mutations in the AAA+ Domains Disrupt Nucleotide-Dependent Substrate Translocation

Two disease-relevant mutations, N432T (linked to SCA28) and R468C (DOA), localize to the vicinity of the nucleotide-binding pocket at the ATPase intersubunit interface (Charif et al., 2015; Colavito et al., 2017; Di Bella et al., 2010). Our structure shows that R468 is one of two Arg-finger residues that projects from




Figure 4. SCA28-Associated Residues of the Protease Domain Mediate Important Intersubunit Contacts

(A) Axial view of the center of the protease ring showing the central protrusion (light purple) and the negatively (red) and positively charged (blue) residues depicted as sticks.

(B) Side view of the central protrusion, colored as in (A), reveals stacked rings of alternating charge that face the central channel.

(C) A close-up of residues 653–703, where all residues linked to SCA28 in the protease domains are found, shows the tightly packed inter- and intrasubunit interaction network at the center of the protease ring. Disease-associated residues are shown as sticks and highlighted in magenta.

(D) Close-up views of SCA28-associated residues at the base of the central protrusion. Top: close-up of the charge cluster at the lateral interface of the protease domains. Disease-related G671 (light purple) is found at the base of the central protrusion (dark purple) in a loop that inserts between helices $\alpha 13$ of neighboring subunits. On the same loop, E668 (red) and K669 (blue) interact with diseaseassociated residues E700 and R702 on helix α 13 (light purple). Bottom: close-up of the interactions between adjacent a12 helices and the central protrusion. S674 (magenta) from the central protease loop packs against T654 (light purple) on helix α 12 of the neighboring subunit. SCA28-associated residue M666 (light purple) is found at the interface between adjacent a12 helices.

See also Table S1.

cantly reduced ATPase activity. N432 is located within helix α 5 immediately adjacent to the ISS motif, suggesting that this

the adjacent large ATPase subdomain to coordinate interactions with the γ -phosphate (Figures 3C and S2B). These Arg-finger residues are highly conserved across classical AAA+ enzymes and are suggested to play roles in ATP binding and/or intersubunit interactions (Wendler et al., 2012). In fact, mutation of analogous Arg-fingers in bacterial FtsH obliterated activity (Karata et al., 1999). Accordingly, the R468C patient mutation abolishes ATP hydrolysis and substrate degradation when incorporated into ^{cchex}AFG3L2 (Figure 2B). Consistent with impaired ATP binding at the intersubunit interface, R468C decreased recovery of AFG3L2 hexamers by SEC, mirroring the behavior of an ATP-binding incompetent Walker A control (K354A, denoted AFG3L2^{WA}) (Figure S4B).

Previously, homology models of FtsH were used to predict that N432T might impair substrate engagement in the central pore (Di Bella et al., 2010). Our structure shows that N432 interacts with R416 within pore-loop 2, positioning this loop to facilitate substrate engagement (Figure 2A). Strict conservation of both N432 and R416 within the FtsH family implies that this interaction exists in other family members (Figure S3A). Both R416A and disease-relevant N432T substitutions abolished substrate degradation in ^{cchex}AFG3L2, indicating a key functional role for this interaction. Surprisingly, these two mutations also signifi-

mutation might disrupt allosteric coordination of ATP hydrolysis. In agreement, N432T displayed a significantly reduced maximal steady-state ATPase rate but retained high affinity for ATP, indicating that this mutation impairs catalysis without impacting nucleotide binding (Figure S4F). Thus, our structure-function studies indicate that the disease-relevant N432T mutation allosterically affects both the ATP hydrolysis cycle and organization of pore-loop 2.

Disease Mutations in the Protease Domain Concentrate Near the Central Protrusion

With the exception of N432T, all SCA28-associated mutations identified to date localize to two hotspots within, or at the base of, the central protease loops. These loops form a channel-like protrusion at the center of the proteolytic ring that interacts with pore-loop 2 and the translocating substrate (Figures 4A–4D). In each subunit, the base of the central protease loop is stabilized by π -stacking intrasubunit interactions between Y689 and F675 (Figure 4C). Intriguingly, layered rings alternating between acidic (E686 and E691) and basic (K687 and R695) residues create a highly charged channel surface (Figures 4A and 4B).

All of the mutations in this region line the channel of the central protrusion and likely impact the integrity of its structure. E691K




Figure 5. Autosomal Dominant Mutations Impair AFG3L2 Function to Different Extents through Three Distinct Molecular Mechanisms (A) ATPase and substrate degradation rates for ^{cchex}AFG3L2 and its variants with SCA28-related substitutions in the protease domain show impaired catalytic activity in all cases, albeit to different extents. Values are means of independent replicates ($n \ge 3$) \pm SD. *** $p \le 0.001$, *** $p \le 0.0001$ as calculated using Student's two-tailed t test and statistical significances are shown relative to WT ^{cchex}AFG3L2.

(B and C) BNPAGE (B) and SDS-PAGE (C) analysis of C-terminally Flag-tagged AFG3L2 containing representative disease mutants (N432T, R468C, M666R, P688T, and E691K) expressed in HEK293T cells reveal distinct effects consistent with the three different biochemical pathways for impairment of AFG3L2 function identified *in vitro*. Non-transfected mock, wild type (WT), Walker A (WA, impaired ATP binding), and Walker B (WB, impaired ATP hydrolysis) were included as controls. See also Table S1.

impacting AFG3L2 function. A collection of residues previously identified as important for assembly of the heterohexameric yeast m-AAA protease also locate to the central

swaps the charge of one of the acidic rings, which would disrupt the charged ring system within the channel (Figure 4B). Similarly, A694E positions a negatively charged residue adjacent to E691, introducing charge repulsion between these residues (Figure 4B). At the base of the central protease loop, substitutions of Y689 (Y689N and Y689H) would eliminate the π -stacking interactions that maintain loop integrity (Figure 4C). Finally, P688 introduces a sharp turn at the base of the loop that correctly positions Y689 and K687 for interaction with other residues in this region (Figure 4C). The P688T substitution will likely add flexibility at this position and decrease the stability of the central protrusion.

In contrast to the central protease loop, residues at the base of the central protrusion are highly conserved across FtsH-related proteases, and our structure indicates that the majority of these residues are involved in intersubunit interactions that stabilize the proteolytic ring. Notably, all remaining SCA28-associated residues are located in this region, including one of the most highly mutated residues in disease, M666, which packs tightly into a hydrophobic pocket at the intersubunit interface (Figure 4D). Mutation of M666 to Thr or Val would perturb this hydrophobic pocket. M666R, which would disrupt this pocket by introducing a positive charge, results in one of the most severe disease phenotypes in patients. R702Q and G671R/E would destabilize a charged cluster at the base of the central protrusion (Figure 4D). Similarly, E700K would disrupt ionic interactions with K669 at the base of the central protrusion in the same subunit (Figure 4D). T654I and S674L would introduce bulky hydrophobic residues into a closely packed intersubunit interface (Figure 4D). Based on these structural observations, we predict that all SCA28-associated mutations localized within or at the base of the central protrusion destabilize the protease, thereby protrusion, further highlighting the importance of this feature in complex stability (Lee et al., 2011).

Incorporating these protease mutations into ^{core}AFG3L32^{WB/PI} significantly impaired recovery of the hexameric protein by SEC, albeit to different extents (Figures S4C and S4D). For example, M666R, which disrupts the hydrophobic interface between protease subunits, completely abolished hexamer recovery, while P688T, which increases flexibility at the base of the protrusion, only modestly affected stability (Figures S4C and S4D). This global destabilization of the catalytic core was further evident when we incorporated protease mutations into ^{cchex}AFG3L2. Despite hexamerization, all protease mutations show reductions in both ATP hydrolysis and substrate degradation that reflect the degree of destabilization observed by SEC (Figure 5A). Moreover, reductions of activity in vitro appear to correlate with disease severity in patients. For instance, P688T presents only a modest reduction in activity and is associated with the mildest condition in SCA28 patients, whereas M666R shows a near complete loss of activity and is associated with a very severe, early onset phenotype in patients (Di Bella et al., 2010; Svenstrup et al., 2017).

To further define the impact of these mutations on AFG3L2 stability, we incorporated the mild mutation P688T and the severe mutations M666R and E691K into C-terminally Flag-tagged AFG3L2 (AFG3L2^{FT}) and monitored assembly and stability by Blue-Native (BN-PAGE) and SDS-PAGE. By BN-PAGE, P688T showed a small increase in AFG3L2 oligomer migration and a small increase in AFG3L2 monomers, indicating modest destabilization (Figure 5B). In contrast, M666R and E691K show significant streaking of the AFG3L2 oligomer band (Figure 5B), consistent with the destabilization of AFG3L2 hexamers




Figure 6. Recessively Inherited Mutations Are Directly Related to the Mechanism of Proteolytic Cleavage

(A) Ribbon representation of the atomic model is shown inside the semi-transparent cryo-EM density of the protease ring. Cryo-EM density corresponding to substrate trapped in the proteolytic active sites is displayed as a solid orange surface. The close-up view to the right shows how the substrate (orange worm) forms an additional β strand next to β 7 and crosses directly above the catalytic triad and the coordinated zinc ion. The disease-related residues A572 and Y616 (green sticks), and Y614 (light green) are shown.

(B) ATPase and substrate degradation rates for $^{\rm cohex}AFG3L2$ and its variants containing the Y616C and A572T substitutions related to distinct autosomal recessive conditions show increased and decreased activity, respectively. Values are means of independent replicates (n \geq 3) \pm SD. $^{**}p \leq$ 0.01, $^{***}p \leq$ 0.001, $^{****}p \leq$ 0.001 as calculated using Student's two-tailed t test and statistical significances are shown relative to WT $^{\rm cohex}AFG3L2$.

(C) Peptide cleavage rate of peptidase active/ ATPase inactive AFG3L2 (^{core}AFG3L2^{WB}) shows that substrate cleavage can occur independently of ATP hydrolysis. Substitutions in the N termini and the central protease loop (^{core}AFG3L2^{WB/L299A} and ^{core}AFG3L2^{WB/M683A}) do not impact ATPindependent proteolytic cleavage, whereas

constructs containing the recessive disease mutations A572T and Y616C (^{core}AFG3L2^{WB/A572T} and ^{core}AFG3L2^{WB/Y616C}) present significantly decreased and increased proteolytic activity, respectively. Values are means of independent replicates ($n \ge 3$) ± SD. *** $p \le 0.001$, **** $p \le 0.0001$ as calculated using Student's two-tailed t test and statistical significances are shown relative to ^{core}AFG3L2^{WB}. NS, no statistical significance. See also Table S1.

observed in vitro (Figures S4C and S4D). The varying levels of AFG3L2 destabilization afforded by these mutations appears to be in part mediated through proteolytic cleavage of the protomer. Using antibodies that recognize the N or C terminus of AFG3L2^{FT}, we observed the accumulation of an N-terminal cleavage product of \sim 50 kDa in SDS-PAGE that corresponds to loss of the C-terminal protease domain for all three of these mutants (Figure 5C). P688T leads to a more modest accumulation of this cleavage product, consistent with the modest effect on oligomer stability (Figures 5C and S4C) and activity (Figure 5A). However, AFG3L2 harboring the M666R or E691K mutation showed significant accumulation of this cleavage product (Figure 5C), reflecting marked destabilization (Figures 5B, S4C, and S4D) and severe reduction in activity (Figure 5A). These results further support a model whereby mutations in the protease domain destabilize the protease ring, leading to SCA28, with the extent of destabilization being an important factor for disease severity and age of onset in patients (Table S1).

Analyzing the ATPase mutants N432T and R468C using the same approach produced starkly contrasting results (Figures 5B and 5C). To determine whether their distinct profiles are related to impairment of the ATP hydrolysis cycle, we expressed control mutants Walker A (prevents ATP binding) and Walker B (prevents ATP hydrolysis). As in our SEC experiments, the Walker B mutant increased stability of the AFG3L2 hexamer, whereas appearance of AFG3L2 monomers in the Walker A

mutant indicates disassembly of the complex. In agreement with our *in vitro* data, R468C closely mirrors the behavior of the Walker A mutant, potentially reflecting the unique DOA pathology observed in patients (Figures 5B and 5C). While the SDS-PAGE profile of N432T is similar to that of the Walker B mutant, N432T causes a mild destabilization of AFG3L2 oligomers by BN-PAGE (Figure 5B). Our biochemical and structural data indicate that N432T may allosterically impact both ATP hydrolysis and pore-loop organization (Figure 2). Thus, the decreased stability observed in cells might be due to impairment of substrate binding, providing a potential explanation for the dominantnegative effect seen for this mutation (Di Bella et al., 2010).

Recessively Inherited Mutations Are Involved in Substrate Cleavage at the Proteolytic Active Site

In contrast to the SCA28 and DOA mutations, two single-point mutations in the protease domain of AFG3L2 are linked to severe neurodegenerative disorders with distinct phenotypes only in homozygotes (Y616C, SPAX5; A572T, as yet unnamed neurodegenerative disease) (Eskandrani et al., 2017; Pierson et al., 2011). We found that both mutations are in close proximity to the protease active site (Figure 6A). In AFG3L2, six zinc-metalloprotease active sites are sequestered to the interior periphery of the proteolytic ring (Figure 6A). At each site, a zinc ion is coordinated for catalysis by H574 and H578 from helix α 10 and D649 in helix α 12 (Figure 6A). The His residues are part of a strictly conserved

HEXXH motif that is required for proteolytic activity (Figure S3B). Next to this motif is the conserved residue A572, which is directed toward a hydrophobic pocket on the opposite side of α 10 from the active site (Figures 6A and S5A). The disease mutation A572T would introduce a polar side chain into this pocket, perturbing the local structure of the active site. In agreement, cchexAFG3L2 containing the A572T mutation shows significantly decreased protein degradation activity and a moderate defect in ATP hydrolysis (Figure 6B). Moreover, introduction of A572T to core AFG3L2^{WB/PI} did not hamper hexamer recovery by SEC, indicating local structural defects rather than global destabilization (Figure S4E).

To confirm that A572T directly affects proteolytic activity, we used an ATPase-inactive/peptidase-active variant of the ^{core}AFG3L2 protein (^{core}AFG3L2^{WB}) to measure the ATP-independent cleavage of a small fluorogenic peptide (Ding et al., 2018). Mutations in the N terminus (^{core}AFG3L2^{WB/L299A}) and central protrusion (^{core}AFG3L2^{WB/M683A}), both of which lower substrate degradation rates in the ATPase active context (Figures 2 and 3), did not alter the peptide cleavage rate, indicating that this assay reports solely on proteolytic activity independent of upstream mechanistic defects (Figure 6C). A572T reduced peptide cleavage rates by 50%, demonstrating that this mutation directly impairs proteolysis at the active site (Figure 6C).

Our structure of catalytically inactive AFG3L2 contained density extending across three of the six protease active sites, which we attribute to substrate peptide that is positioned for cleavage (Figure 6A). This substrate appears to form an additional β strand next to β 7, positioning the polypeptide above the catalytic triad. AFG3L2 preferentially cleaves sequences containing Phe residues in the P1' position, immediately C-terminal of the scissile bond (Ding et al., 2018). The position of the substrate in our structure locates the putative specificity site (S1') to a hydrophobic pocket created by V571, L603, and G645 from a single subunit and L615 from the adjacent subunit (Figure S5B). Although no density is observed for the side chain of the substrate residue closest to this position, a Phe side chain can be easily accommodated in this pocket. L615 is part of a non-conserved loop (Y614, L615, and Y616) at the intersubunit interface, and density for the substrate backbone is seen positioned between the side chains of Y614 and the SPAX5-related residue Y616 (Figures 6A and S5B). Strikingly, the disease mutation Y616C displayed increased ATPase and protein degradation rates, with a modest reduction in complex stability (Figures 6B and S4E). Moreover, ATP-independent peptidase activity was 2-fold higher for Y616C compared to controls (Figure 6C). These results suggest that substitution of Y616 with a smaller Cys may reduce steric hindrance of incoming polypeptides, increasing accessibility to the S1⁷ pocket. The distinct gain-of-function effect of Y616C provides a plausible explanation for the unique phenotype of this mutation in patients.

DISCUSSION


A hand-over-hand conveyance of substrate along the central pore of a spiraling ATPase ring is emerging as the conserved mechanism that enables ATP-driven substrate translocation across much of the AAA+ superfamily. However, a fundamental question remains unanswered: "What are the unique evolu-

tionary adaptations that enable different AAA+ proteins to process their distinct substrates?" Our structure of AFG3L2 with substrate bound in both the ATPase and protease domains reveals how an intricate network within the AFG3L2 hexamer coordinates ATP-driven substrate engagement, translocation, and transfer across the degradation chamber for proteolysis. We show that unique structural features integrate with a core nucleotide-dependent mechanism to drive substrate processing, and the functional relevance of these distinctive features is underscored by our finding that disease-linked mutations are concentrated at these substrate-interacting, non-conserved regions. We further show how disease-relevant substitutions differentially impact AFG3L2 activity and stability, providing a molecular basis for AFG3L2-associated neurodegenerative conditions.

An important first step for AAA+ activity is the recognition of the appropriate substrates for processing. While the C termini of FtsH-related AAA+ proteases have been shown to modulate substrate specificity, the mechanisms responsible for this modulation are unknown (Akiyama, 1999). Our structure reveals that the C terminus of AFG3L2 establishes interdomain interactions between neighboring subunits that stabilize the hexamer, while simultaneously positioning a highly charged tail for interactions at the membrane surface (Figure 7A). This organization is required for AFG3L2 activity and is in contrast to the organization of the C terminus in YME1, which we previously observed to be an unstructured loop extending away from the protease ring into the IMS (Figure 7B). Thus, we speculate that distinct C termini evolved in m- and i-AAA proteases, enabling charge-driven interactions for recruitment of membrane-embedded substrates in AFG3L2 and mediating recognition of soluble IMS substrates in YME1. In line with this hypothesis, alteration of the C terminus of YME1 affects processing of soluble substrates of YME1, but not membrane-embedded substrates (Graef et al., 2007).

In the central pore of the ATPase spiral observed in many AAA+ ATPases, the conserved aromatic residue in pore-loop 1 forms a staircase around the substrate that drives translocation. However, in AFG3L2, the residue immediately adjacent to the poreloop 1 aromatic links consecutive pore loops to form a tightly packed and continuous chain of residues that surround the substrate. Similarly, both the N termini of the ATPases and pore-loop 2 are not conserved and form additional spiral staircases that contact the substrate. Integration of these unique features with the core machinery for nucleotide-driven allosteric changes allows all elements to cooperate in pulling on substrate as ATP is hydrolyzed (Figure 7A). Additionally, the extended pore-loop 2 of AFG3L2 mediates transfer of the substrate to the central protrusion of the protease. These ancillary substrate-interacting elements are not present in YME1, where the translocating substrate enters a large, unoccupied degradation chamber (Figure 7B). Thus, our data demonstrate how the cumulative effect of single-point substitutions and/or small insertions around the core elements alters how substrate is handled in different AAA+ proteins (Figure 7B). These changes are likely to affect not only substrate specificity but also fundamental enzymatic characteristics such as grip on substrate and unfoldase efficacy.


AAA+ proteases are required to degrade substrates with highly diverse sequences. However, evidence exists for site-specific cleavage for some substrates. The presence of substrate in the



1. Substrate engagement 2. ATP-driven translocation by the N- and C-termini

by the pore-1 loops

3. Handoff from pore-2 4. Substrate cleavage at the loops to central protrusion peptidase active sites



protease active site in our AFG3L2 structure offers insights into this enzymatic "decision." We observe that the substrate is stabilized in the active site by backbone-mediated interactions compatible with sequence-independent cleavage for broad house-keeping activity. However, our structure also reveals a putative specificity pocket (S1') that is capable of accommodating an aromatic residue, consistent with the moderate degree of preference for Phe immediately C-terminal of the scissile bond (P1') (Ding et al., 2018). Moreover, the specificity pocket involves residues from the adjacent subunit, suggesting that heterohexameric m-AAA proteases may display altered substrate specificity. These results will guide future studies to determine how substrate interactions in the proteolytic active site might influence sequence preference in different AAA+ proteases and promote site-specific processing of substrates.

Importantly, how different mutations in AFG3L2 lead to distinct neurological phenotypes is an important, open question in the field. Here, we show that mutations associated with different diseases influence distinct aspects of AFG3L2 stability and activity. Interestingly, the distinct biochemical impact of different mutations appears to correlate with unique phenotypes and inheritance patterns, suggesting that these differences might constitute the molecular basis for the different neurodegenerative conditions associated with AFG3L2 in patients (Table S1). While the functional impact of these different AFG3L2 mutations on mitochondrial proteostasis and function remain to be established, our work provides a molecular basis to begin to understand the distinct structure-phenotype relationship observed in patients harboring different mutations in this critical AAA+ protease.

STAR***METHODS**

Detailed methods are provided in the online version of this paper and include the following:

Figure 7. Model for Substrate Processing by AAA+ Proteases of the Mitochondrial Inner Membrane

(A) Step-by-step model for processing of membraneassociated substrates by AFG3L2. From left to right: (1) the N and C termini (blue and red, respectively) recruit and engage substrate (orange) at the membrane interface; (2) pore-loops 1 (cyan) intercalate into the substrate to drive hand-over-hand ATP-powered translocation; (3) pore-loops 2 (green) and the central protrusion of the protease (purple) mediate transfer of the unfolded polypeptide across the proteolytic chamber: and (4) the substrate forms an additional β strand above the zinc coordinated active site and is positioned for cleavage (star).

(B) Side-by-side comparison of human m-AAA+ protease AFG3L2 and yeast i-AAA+ protease YME1 emphasizes how small insertions in the pore-loop 2 (green) and central protrusion (purple) dramatically impact the handling of a polypeptide substrate (orange), as well as the organization of the degradation chamber. We further highlight the organization of the non-conserved C termini (red) and the resulting differential orientation of the charged C-terminal tails (dotted red lines).

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Microbe Strains
 - Cell Lines
- METHOD DETAILS
 - Cloning, Expression and Purification
 - Biochemical Assays
 - Size Exclusion Chromatography (SEC) assay
 - Sample preparation for electron microscopy
 - Electron microscopy data acquisition
 - Image processing
 - Atomic model building and refinement
 - Cell Culture and Mitochondrial isolation
 - SDS- and BN-PAGE analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. molcel.2019.06.016.

ACKNOWLEDGMENTS

We thank J.C. Ducom at The Scripps Research Institute (TSRI) High Performance Computing for computational support and B. Anderson for electron microscope support at TSRI. We thank L. Yang at Stony Brook University (SBU) for assistance with figure preparation, Z. Piazza (SBU) for assistance with cloning, and W. Karzai (SBU) for access to instrumentation. We thank M. Shin (TSRI) and A. Rampello for helpful discussions. C.P. is supported by an American Heart Association predoctoral fellowship. G.C.L. is supported as a Pew Scholar, by a young investigator award from Amgen, and by the NIH (DP2EB020402 and R21AG061697). Computational analyses of EM data were performed using shared instrumentation funded by NIH (S10OD021634 to G.C.L.). S.E.G. is supported by NIH (R01GM115898). R.L.W. is supported by NIH (R01NS095892).

AUTHOR CONTRIBUTIONS

B.D. cloned and purified proteases and substrates. C.P. performed cryo-EM, image analysis, and reconstructions. C.P. and S.E.G. built the atomic model. B.D. performed *in vitro* biochemical experiments. C.P. and A.S. performed *in vivo* experiments. All authors contributed to analysis and interpretations of the experimental results and data. C.P., B.D., R.L.W., G.C.L., and S.E.G. wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: January 5, 2019 Revised: April 24, 2019 Accepted: June 13, 2019 Published: July 18, 2019

REFERENCES

Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., Headd, J.J., Moriarty, N.W., Mustyakimov, M., Terwilliger, T.C., Urzhumtsev, A., Zwart, P.H., and Adams, P.D. (2012). Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. *68*, 352–367.

Akiyama, Y. (1999). Self-processing of FtsH and its implication for the cleavage specificity of this protease. Biochemistry *38*, 11693–11699.

Almajan, E.R., Richter, R., Paeger, L., Martinelli, P., Barth, E., Decker, T., Larsson, N.G., Kloppenburg, P., Langer, T., and Rugarli, E.I. (2012). AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival. J. Clin. Invest. *122*, 4048–4058.

Arlt, H., Steglich, G., Perryman, R., Guiard, B., Neupert, W., and Langer, T. (1998). The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease. EMBO J. *17*, 4837–4847.

Augustin, S., Gerdes, F., Lee, S., Tsai, F.T., Langer, T., and Tatsuta, T. (2009). An intersubunit signaling network coordinates ATP hydrolysis by m-AAA proteases. Mol. Cell *35*, 574–585.

Banfi, S., Bassi, M.T., Andolfi, G., Marchitiello, A., Zanotta, S., Ballabio, A., Casari, G., and Franco, B. (1999). Identification and characterization of AFG3L2, a novel paraplegin-related gene. Genomics *59*, 51–58.

Bittner, L.M., Arends, J., and Narberhaus, F. (2017). When, how and why? Regulated proteolysis by the essential FtsH protease in Escherichia coli. Biol. Chem. *398*, 625–635.

Bohovych, I., Chan, S.S., and Khalimonchuk, O. (2015). Mitochondrial protein quality control: the mechanisms guarding mitochondrial health. Antioxid. Redox Signal. *22*, 977–994.

Cagnoli, C., Mariotti, C., Taroni, F., Seri, M., Brussino, A., Michielotto, C., Grisoli, M., Di Bella, D., Migone, N., Gellera, C., et al. (2006). SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22q11.2. Brain *129*, 235–242.

Charif, M., Roubertie, A., Salime, S., Mamouni, S., Goizet, C., Hamel, C.P., and Lenaers, G. (2015). A novel mutation of AFG3L2 might cause dominant optic atrophy in patients with mild intellectual disability. Front. Genet. *6*, 311.

Chen, B., Retzlaff, M., Roos, T., and Frydman, J. (2011). Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 3, a004374.

Colavito, D., Maritan, V., Suppiej, A., Del Giudice, E., Mazzarolo, M., Miotto, S., Farina, S., Dalle Carbonare, M., Piermarocchi, S., and Leon, A. (2017). Nonsyndromic isolated dominant optic atrophy caused by the p.R468C mutation in the AFG3 like matrix AAA peptidase subunit 2 gene. Biomed. Rep. 7, 451–454.

Consolato, F., Maltecca, F., Tulli, S., Sambri, I., and Casari, G. (2018). m-AAA and i-AAA complexes coordinate to regulate OMA1, the stress-activated supervisor of mitochondrial dynamics. J. Cell Sci. *131*, jcs213546.

de la Peña, A.H., Goodall, E.A., Gates, S.N., Lander, G.C., and Martin, A. (2018). Substrate-engaged 26S proteasome structures reveal mechanisms for ATP-hydrolysis-driven translocation. Science *362*, 1018.

Di Bella, D., Lazzaro, F., Brusco, A., Plumari, M., Battaglia, G., Pastore, A., Finardi, A., Cagnoli, C., Tempia, F., Frontali, M., et al. (2010). Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat. Genet. *42*, 313–321.

Ding, B., Martin, D.W., Rampello, A.J., and Glynn, S.E. (2018). Dissecting Substrate Specificities of the Mitochondrial AFG3L2 Protease. Biochemistry 57, 4225–4235.

Edener, U., Wöllner, J., Hehr, U., Kohl, Z., Schilling, S., Kreuz, F., Bauer, P., Bernard, V., Gillessen-Kaesbach, G., and Zühlke, C. (2010). Early onset and slow progression of SCA28, a rare dominant ataxia in a large four-generation family with a novel AFG3L2 mutation. Eur. J. Hurn. Genet. *18*, 965–968.

Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. *60*, 2126–2132.

Eskandrani, A., AlHashem, A., Ali, E.S., AlShahwan, S., Tlili, K., Hundallah, K., and Tabarki, B. (2017). Recessive AFG3L2 Mutation Causes Progressive Microcephaly, Early Onset Seizures, Spasticity, and Basal Ganglia Involvement. Pediatr. Neurol. *71*, 24–28.

Gates, S.N., Yokom, A.L., Lin, J., Jackrel, M.E., Rizo, A.N., Kendsersky, N.M., Buell, C.E., Sweeny, E.A., Mack, K.L., Chuang, E., et al. (2017). Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. Science 357, 273–279.

Geissler, A., Chacinska, A., Truscott, K.N., Wiedemann, N., Brandner, K., Sickmann, A., Meyer, H.E., Meisinger, C., Pfanner, N., and Rehling, P. (2002). The mitochondrial presequence translocase: an essential role of Tim50 in directing preproteins to the import channel. Cell *111*, 507–518.

Glynn, S.E. (2017). Multifunctional Mitochondrial AAA Proteases. Front. Mol. Biosci. 4, 34.

Goddard, T.D., Huang, C.C., and Ferrin, T.E. (2007). Visualizing density maps with UCSF Chimera. J. Struct. Biol. *157*, 281–287.

Graef, M., Seewald, G., and Langer, T. (2007). Substrate recognition by AAA+ ATPases: distinct substrate binding modes in ATP-dependent protease Yme1 of the mitochondrial intermembrane space. Mol. Cell. Biol. *27*, 2476–2485.

Haynes, C.M., Yang, Y., Blais, S.P., Neubert, T.A., and Ron, D. (2010). The matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in C. elegans. Mol. Cell *37*, 529–540.

Herzik, M.A., Jr., Wu, M., and Lander, G.C. (2017). Achieving betterthan-3-Å resolution by single-particle cryo-EM at 200 keV. Nat. Methods *14*, 1075–1078.

Herzik, M.A., Jr., Fraser, J.S., and Lander, G.C. (2019). A Multi-model Approach to Assessing Local and Global Cryo-EM Map Quality. Structure *27*, 344–358.

Heymann, J.B. (2018). Guidelines for using Bsoft for high resolution reconstruction and validation of biomolecular structures from electron micrographs. Protein Sci. 27, 159–171.

losefson, O., Nager, A.R., Baker, T.A., and Sauer, R.T. (2015). Coordinated gripping of substrate by subunits of a AAA+ proteolytic machine. Nat. Chem. Biol. *11*, 201–206.

Janska, H., Kwasniak, M., and Szczepanowska, J. (2013). Protein quality control in organelles - AAA/FtsH story. Biochim. Biophys. Acta *1833*, 381–387.

Karata, K., Inagawa, T., Wilkinson, A.J., Tatsuta, T., and Ogura, T. (1999). Dissecting the role of a conserved motif (the second region of homology) in the AAA family of ATPases. Site-directed mutagenesis of the ATP-dependent protease FtsH. J. Biol. Chem. *274*, 26225–26232.

Kondadi, A.K., Wang, S., Montagner, S., Kladt, N., Korwitz, A., Martinelli, P., Herholz, D., Baker, M.J., Schauss, A.C., Langer, T., and Rugarli, E.I. (2014). Loss of the m-AAA protease subunit AFG_3L_2 causes mitochondrial transport defects and tau hyperphosphorylation. EMBO J. 33, 1011–1026.

König, T., Tröder, S.E., Bakka, K., Korwitz, A., Richter-Dennerlein, R., Lampe, P.A., Patron, M., Mühlmeister, M., Guerrero-Castillo, S., Brandt, U., et al. (2016). The m-AAA Protease Associated with Neurodegeneration Limits MCU Activity in Mitochondria. Mol. Cell *64*, 148–162.

Koppen, M., Metodiev, M.D., Casari, G., Rugarli, E.I., and Langer, T. (2007). Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia. Mol. Cell. Biol. 27, 758–767.

Lander, G.C., Stagg, S.M., Voss, N.R., Cheng, A., Fellmann, D., Pulokas, J., Yoshioka, C., Irving, C., Mulder, A., Lau, P.W., et al. (2009). Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. *166*, 95–102.

Langklotz, S., Baumann, U., and Narberhaus, F. (2012). Structure and function of the bacterial AAA protease FtsH. Biochim. Biophys. Acta *1823*, 40–48.

Lee, S., Augustin, S., Tatsuta, T., Gerdes, F., Langer, T., and Tsai, F.T. (2011). Electron cryomicroscopy structure of a membrane-anchored mitochondrial AAA protease. J. Biol. Chem. *286*, 4404–4411.

Leonhard, K., Herrmann, J.M., Stuart, R.A., Mannhaupt, G., Neupert, W., and Langer, T. (1996). AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic system for the ATP-dependent degradation of inner membrane proteins in mitochondria. EMBO J. *15*, 4218–4229.

Levytskyy, R.M., Germany, E.M., and Khalimonchuk, O. (2016). Mitochondrial Quality Control Proteases in Neuronal Welfare. J. Neuroimmune Pharmacol. *11*, 629–644.

Löbbe, A.M., Kang, J.S., Hilker, R., Hackstein, H., Müller, U., and Nolte, D. (2014). A novel missense mutation in AFG3L2 associated with late onset and slow progression of spinocerebellar ataxia type 28. J. Mol. Neurosci. *52*, 493–496.

Maltecca, F., Aghaie, A., Schroeder, D.G., Cassina, L., Taylor, B.A., Phillips, S.J., Malaguti, M., Previtali, S., Guénet, J.L., Quattrini, A., et al. (2008). The mitochondrial protease AFG3L2 is essential for axonal development. J. Neurosci. 28, 2827–2836.

Maltecca, F., Magnoni, R., Cerri, F., Cox, G.A., Quattrini, A., and Casari, G. (2009). Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration. J. Neurosci. *29*, 9244–9254.

Mancini, C., Hoxha, E., Iommarini, L., Brussino, A., Richter, U., Montarolo, F., Cagnoli, C., Parolisi, R., Gondor Morosini, D.I., Nicolò, V., et al. (2019). Mice harbouring a SCA28 patient mutation in AFG3L2 develop late-onset ataxia associated with enhanced mitochondrial proteotoxicity. Neurobiol. Dis. *124*, 14–28.

Mariotti, C., Brusco, A., Di Bella, D., Cagnoli, C., Seri, M., Gellera, C., Di Donato, S., and Taroni, F. (2008). Spinocerebellar ataxia type 28: a novel autosomal dominant cerebellar ataxia characterized by slow progression and ophthalmoparesis. Cerebellum 7, 184–188.

Monroe, N., Han, H., Shen, P.S., Sundquist, W.I., and Hill, C.P. (2017). Structural basis of protein translocation by the Vps4-Vta1 AAA ATPase. eLife 6, e24487.

Nishimura, K., Kato, Y., and Sakamoto, W. (2016). Chloroplast proteases: updates on proteolysis within and across suborganellar compartments. Plant Physiol. *171*, 2280–2293.

Nolden, M., Ehses, S., Koppen, M., Bernacchia, A., Rugarli, E.I., and Langer, T. (2005). The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell *123*, 277–289.

Pierson, T.M., Adams, D., Bonn, F., Martinelli, P., Cherukuri, P.F., Teer, J.K., Hansen, N.F., Cruz, P., Mullikin For The Nisc Comparative Sequencing Program, J.C., Blakesley, R.W., et al. (2011). Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet. 7, e1002325.

Puchades, C., Rampello, A.J., Shin, M., Giuliano, C.J., Wiseman, R.L., Glynn, S.E., and Lander, G.C. (2017). Structure of the mitochondrial inner membrane

AAA+ protease YME1 gives insight into substrate processing. Science 358, eaao0464.

Rampello, A.J., and Glynn, S.E. (2017). Identification of a Degradation Signal Sequence within Substrates of the Mitochondrial i-AAA Protease. J. Mol. Biol. *429*, 873–885.

Ripstein, Z.A., Huang, R., Augustyniak, R., Kay, L.E., and Rubinstein, J.L. (2017). Structure of a AAA+ unfoldase in the process of unfolding substrate. eLife 6, e25754.

Rohou, A., and Grigorieff, N. (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. *192*, 216–221.

Roseman, A.M. (2004). FindEM–a fast, efficient program for automatic selection of particles from electron micrographs. J. Struct. Biol. *145*, 91–99.

Sauer, R.T., and Baker, T.A. (2011). AAA+ proteases: ATP-fueled machines of protein destruction. Annu. Rev. Biochem. *80*, 587–612.

Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. *180*, 519–530.

Shi, H., Rampello, A.J., and Glynn, S.E. (2016). Engineered AAA plus proteases reveal principles of proteolysis at the mitochondrial inner membrane. Nat. Commun. 7, 13301.

Suloway, C., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J., Stagg, S., Potter, C.S., and Carragher, B. (2005). Automated molecular microscopy: the new Leginon system. J. Struct. Biol. *151*, 41–60.

Svenstrup, K., Nielsen, T.T., Aidt, F., Rostgaard, N., Duno, M., Wibrand, F., Vinther-Jensen, T., Law, I., Vissing, J., Roos, P., et al. (2017). SCA28: novel mutation in the AFG3L2 proteolytic domain causes a mild cerebellar syndrome with selective type-1 muscle fiber atrophy. Cerebellum *16*, 62–67.

Szpisjak, L., Nemeth, V.L., Szepfalusi, N., Zadori, D., Maroti, Z., Kalmar, T., Vecsei, L., and Klivenyi, P. (2017). Neurocognitive characterization of an SCA28 family caused by a novel AFG3L2 gene mutation. Cerebellum *16*, 979–985.

Tatsuta, T., Augustin, S., Nolden, M., Friedrichs, B., and Langer, T. (2007). m-AAA protease-driven membrane dislocation allows intramembrane cleavage by rhomboid in mitochondria. EMBO J. *26*, 325–335.

Wagner, R., Aigner, H., and Funk, C. (2012). FtsH proteases located in the plant chloroplast. Physiol. Plant. *145*, 203–214.

Wendler, P., Ciniawsky, S., Kock, M., and Kube, S. (2012). Structure and function of the AAA+ nucleotide binding pocket. Biochim. Biophys. Acta *1823*, 2–14.

Yu, H., Lupoli, T.J., Kovach, A., Meng, X., Zhao, G., Nathan, C.F., and Li, H. (2018). ATP hydrolysis-coupled peptide translocation mechanism of *Mycobacterium tuberculosis* ClpB. Proc. Natl. Acad. Sci. USA *115*, E9560–E9569.

Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods *14*, 331–332.

Zivanov, J., Nakane, T., Forsberg, B.O., Kimanius, D., Hagen, W.J., Lindahl, E., and Scheres, S.H. (2018). New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166.

Zühlke, C., Mikat, B., Timmann, D., Wieczorek, D., Gillessen-Kaesbach, G., and Bürk, K. (2015). Spinocerebellar ataxia 28: a novel AFG3L2 mutation in a German family with young onset, slow progression and saccadic slowing. Cerebellum Ataxias *2*, 19.

STAR*METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies	JUUNUE	
AFG3L2 antibody [N1N2], N-term	GeneTex	Cat# GTX102036; RRID:AB_11171320
Monoclonal ANTI-FLAG M2 antibody		Cat# F1804; RRID:AB_262044
	Sigma	
Monoclonal Anti-alpha-Tubulin antibody produced in mouse	Sigma	Cat# T6074; RRID:AB_477582
Bacterial and Virus Strains		
BL21-CodonPlus (DE3)-RIL	Agilent	Cat# 230245
DH5-Alpha	NEB	Cat# C2987H
Chemicals, Peptides, and Recombinant Prote		
NADH, disodium salt trihydrate	Amresco	Cat# 0348
Pyruvate kinase from rabbit muscle	Sigma	Cat# P9136
Lactate dehydrogenase from rabbit muscle	Calbiochem	Cat# 27217
Adenosine-50triphosphate (ATP)	Roche	Cat# 10127531001
Phosphoenolpyruvate potassium salt	Bachem	Cat# 4014027. 0005
Leu-(3-NO ₂ -Tyr)-Phe-Gly-(Lys-Abz)	GenScript	N/A
Deposited Data	· · · · · · ·	
substrate-bound human m-AAA protease	Protein Data Bank (PDB)	PDB: 6NYY
AFG3L2 atomic cooridinates		
substrate-bound human m-AAA protease AFG3L2 cryo-EM map	Electron Microscopy Data Bank (EMDB)	EMD-0552
Mitochondrial ATPase Protease YME1	Protein Data Bank (PDB); Puchades et al., 2017	PDB: 6AZ0
Experimental Models: Cell Lines	· · · · · · · · · · · · · · · · · · ·	
Human embryonic kidney (HEK) 293T cells	ATCC	N/A
	7.1.00	
Oligonucleotides		
Oligonucleotides		
Oligonucleotides See Table S3	Ding et al., 2018	PMID: 29932645
Oligonucleotides See Table S3 Recombinant DNA		
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB}	Ding et al., 2018	PMID: 29932645
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI}	Ding et al., 2018 Ding et al., 2018	PMID: 29932645 PMID: 29932645
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A}	Ding et al., 2018 Ding et al., 2018 This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A}	Ding et al., 2018 Ding et al., 2018 This Study This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/A572T} 2G-T- ^{core} AFG3L2 ^{WB/Y616C}	Ding et al., 2018 Ding et al., 2018 This Study This Study This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA}	Ding et al., 2018 Ding et al., 2018 This Study This Study This Study This Study This Study This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A N/A N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA}	Ding et al., 2018 Ding et al., 2018 This Study This Study This Study This Study This Study This Study This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A N/A N/A N/A N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA}	Ding et al., 2018 Ding et al., 2018 This Study This Study This Study This Study This Study This Study This Study This Study This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A N/A N/A N/A N/A N/A N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/PI/6C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/R468C}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/A572T} 2G-T- ^{core} AFG3L2 ^{WB/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/WA} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N4572T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N4572T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N4572T}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N4572T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N572T} 2G-T- ^{core} AFG3L2 ^{WB/PI/Y616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/Y616C}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/PI68C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N4572T} 2G-T- ^{core} AFG3L2 ^{WB/PI/N616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N616C} 2G-T- ^{core} AFG3L2 ^{WB/PI/N616C}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/L299A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/PI/M66C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666V} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666V}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A
Oligonucleotides See Table S3 Recombinant DNA 2G-T- ^{core} AFG3L2 ^{WB} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/PI} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/M683A} 2G-T- ^{core} AFG3L2 ^{WB/PI/M68C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M432T} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M468C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666C} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R} 2G-T- ^{core} AFG3L2 ^{WB/PI/M666R}	Ding et al., 2018 Ding et al., 2018 This Study This Study	PMID: 29932645 PMID: 29932645 N/A N/A

(Continued on next page)

Continued			
REAGENT or RESOURCE	SOURCE	IDENTIFIER	
2G-T- ^{core} AFG3L2 ^{WB/PI/S674L}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/P688T}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Y689N}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Y689H}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/E691K}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/A694E}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/E700K}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/R702Q}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Δ272-281}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Δ272-295}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Δ781-797}	This Study	N/A	
2G-T- ^{core} AFG3L2 ^{WB/PI/Δ750-797}	This Study	N/A	
2G-T- ^{cchex} AFG3L2	Ding et al., 2018	PMID: 29932645	
2G-T- ^{cchex} AFG3L2 ^{F289A}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{L299A}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M380V}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M380K}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{F381A}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{F421A}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{N432T}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{R468C}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{A572T}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{Y616C}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{T654I}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M666R}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M666V}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M666T}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{G671E}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{G671R}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{S674L}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{M683A}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{P688T}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{Y689N}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{Y689H}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{E691K}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{A694E}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{E700K}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{R702Q}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{W779R}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{∆272-281}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{∆272-295}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{∆781-797}	This Study	N/A	
2G-T- ^{cchex} AFG3L2 ^{∆750-797}	This Study	N/A	
pCOLADuet-1- ^{SF} GFP-10/11 ^{A226G} -β20	Ding et al., 2018	PMID: 29932645	
pcDNA3.1-AFG3L2 ^{WT} -Flag	This study	N/A	
pcDNA3.1-AFG3L2 ^{WB} -Flag	This study	N/A	
pcDNA3.1-AFG3L2 ^{WA} -Flag	This study	N/A	
pcDNA3.1-AFG3L2 ^{N432T} -Flag	This study	N/A	
	,	Continues	

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
pcDNA3.1-AFG3L2 ^{R468C} -Flag	This study	N/A
pcDNA3.1-AFG3L2 ^{M666R} -Flag	This study	N/A
pcDNA3.1-AFG3L2 ^{P688T} -Flag	This study	N/A
pcDNA3.1-AFG3L2 ^{E691K} -Flag	This study	N/A
Software and Algorithms		
Chimera	Goddard et al., 2007	https://www.cgl.ucsf.edu/chimera/
Coot	Emsley and Cowtan, 2004	https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
Relion 3.0	Zivanov et al., 2018	https://www3.mrc-lmb.cam.ac.uk/relion/index.php?title= Main_Page
FindEM	Roseman, 2004	https://omictools.com/findem-tool
Phenix	Afonine et al., 2012	http://www.phenix-online.org/
Leginon	Suloway et al., 2005	http://emg.nysbc.org/redmine/projects/leginon/wiki/ Leginon_Homepage
Appion	Lander et al., 2009	http://emg.nysbc.org/redmine/projects/appion/wiki/ Appion_Home
MotionCorr2	Zheng et al., 2017	https://harc.ucsf.edu/harc-resources
CTFFind4	Rohou and Grigorieff, 2015	http://grigoriefflab.janelia.org/ctffind4
GraphPad Prism	GraphPad Software	https://www.graphpad.com/scientific-software/prism/
MATLAB	MathWorks	https://www.mathworks.com/products/matlab.html
Kaleidagraph	Synergy Software	http://www.synergy.com/wordpress_650164087/kaleidagraph/
Relion 1.4	Scheres, 2012	https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Main_Page

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Steven E. Glynn (steven.glynn@stonybrook.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Microbe Strains

Escherichia coli DH5 α were grown in LB broth supplemented with 100 μ g/ml ampicillin at 37°C. *Escherichia coli* BL21-CodonPlus (DE3)-RIL were grown in LB broth supplemented with 100 μ g/ml ampicillin and 34 μ g/ml chloramphenicol at 37°C.

Cell Lines

Human embryonic kidney (HEK) 293T are female and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gemini), 1% penicillin-streptomycin, 1% glutamine at 37°C and 5% CO₂.

METHOD DETAILS

Cloning, Expression and Purification

All molecular cloning was performed using *E. Coli* DH5- α Competent Cells (NEB) (Key Resources Table). Plasmids containing sequences encoding ^{cchex}AFG3L2 and ^{core}AFG3L2 were constructed by subcloning a sequence encoding residues 272-797 of human AFG3L2 into a 2G-T vector and a modified 2G-T vector containing a cc-hex sequence respectively (Ding et al., 2018). Truncated AFG3L2 variants were constructed similarly using the primers listed in the Table S3. Mutant AFG3L2 constructs were created by site-directed mutagenesis using the primers listed in the Table S3. All AFG3L2 enzymes were expressed in *E. coli* BL21-CodonPlus (Key Resources Table) cells by induction at OD₆₀₀~0.6 with 0.2 mM IPTG at 16°C for 14 h. For biochemical and biophysical characterization assays, cells containing AFG3L2 constructs were centrifuged at 4000 rpm for 30 min. Cell pellets containing ^{cchex}AFG3L2 or variants were resuspended in lysis buffer (20 mM Tris-HCl, pH 7.8, 300 mM NaCl, 10% Glycerol, 0.1 mM EDTA and 10 mM β -mercaptoethanol) supplemented with 10 mM PMSF, and lysed by sonication. Cell lysates were centrifuged at 14000 rpm for 30 min and the supernatants loaded to a Glutathione Superflow Agarose column (Pierce). Unbound proteins were washed off by addition of 10 column volumes of lysis buffer and bound proteins eluted by addition of lysis buffer supplemented with 10 mM incubated at 4°C for 16 h. Cleaved ^{cchex}AFG3L2 proteins were then applied to a Ni-NTA column (Thermo Scientific) and collected in the flow-through. Proteins were concentrated and loaded onto a Superose 6 10/300 GL Increase size exclusion column (GE Healthcare) equilibrated with SEC buffer (20 mM Tris-HCl, pH 7.8, 100 mM NaCl, 10% Glycerol, 0.1 mM EDTA and 1 mM DTT). ^{core}AFG3L2^{WB}, ^{core}AFG3L2^{WB/PI} and their variants were purified using a similar protocol with the following modifications. Lysis buffer contained 50 mM HEPES-HCl, pH 7.5, 300 mM KCl, 0.1 mM EDTA, 10% glycerol and 10 mM β -mercaptoethanol, and SEC buffer contained 25 mM HEPES-HCl, pH 7.5, 100 mM KCl, 10% glycerol, and 1 mM DTT. Size exclusion chromatography was performed using a Superdex 200 Increase 10/300 GL Increase column (GE Healthcare). For cryo-EM structure determination, ^{core}AFG3L2^{WB/PI} was further purified by the following modifications to the protocol. Prior to size exclusion chromatography, ^{core}AFG3L2^{WB/PI} was exchanged into buffer containing 50 mM HEPES-HCl, pH 7.5, 150 mM KCl, 2 mM EDTA, 10% glycerol, and 10 mM β -mercaptoethanol. After buffer exchange, 15 mM MgCl₂ and 1 mM AMP-PNP were added to the protein sample, and the mixture was incubated for 4 h on ice. The concentrated protein sample was then applied to a Superdex 200 Increase 10/300 GL Increase column (GE Healthcare) equilibrated with buffer containing 25 mM HEPES-HCl, pH 7.5, 100 mM KCl, 20 μ M AMP-PNP, 10 mM MgCl₂, 10% glycerol and 1 mM DTT. Fractions corresponding to the calculated elution volume of related AFG3L2 hexamers were pooled, concentrated, flash-frozen, and stored at -80° C.

The ^{SF}GFP-10/11^{A226G}- β 20 model substrate was produced by inserting a sequence encoding the β 20 degron into a plasmid encoding ^{SF}GFP-10/11^{A226G}, which was a gift from Prof. Robert Sauer (MIT) (losefson et al., 2015). Proteins were expressed in *E. coli* BL21-CodonPlus cells by growth at 37°C followed by addition of 1 mM IPTG and growth at 16°C for 14 h. Cells were centrifuged at 14,000 rpm for 30 min and resuspended in lysis buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 10 mM imid-azole, and 10 mM β -mercaptoethanol. The supernatants were applied to a Ni-NTA column (Thermo Scientific) followed by washing with buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 250 mM imidazole, and 10 mM β -mercaptoethanol. Size exclusion chromatography was performed using a Superdex 200 Increase 10/300 GL Increase column (GE Healthcare) equilibrated with buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, and 1 mM DTT. The fractions corresponding to the correct protein were collected, concentrated, and flash frozen with liquid nitrogen for storage at -80° C.

Biochemical Assays

ATPase activity, fluorescence-based protein degradation, and fluorogenic peptide cleavage assays were performed as previously described with some modifications (Ding et al., 2018; Rampello and Glynn, 2017). ATPase assays, as a coupled-enzyme assay monitoring the loss of NADH at 340 nm, were carried out at 37°C in a 384-well clear bottom plate (Corning) using a SpectraMax M5 plate reader (Molecular Devices) with 1 µM ^{cchex}AFG3L2 or its variants. Reaction buffer contains 25 mM HEPES-KOH, pH 7.5, 5 mM MgCl₂, 10% glycerol, 1 mM NADH, 21.5 U ml⁻¹ lactate dehydrogenase and an ATP regeneration system (2 mM ATP, 7.5 mM phosphoenolpyruvate and 18.8 U ml⁻¹ pyruvate kinase) (Key Resources Table). For fluorescence-based protein degradation assay, the reactions were carried out in a 384-well black plate (ex = 467 nm; em = 511 nm) at 37°C with 1 μM ^{cchex}AFG3L2 or its variants and 20 μM ^{SF}GFP-10/11^{A226G}-620. The initial time points with linear decrease in 340 nm signal were used to calculate the ATPase rates. Steady-state ATPase data were fit to the Hill version of the Michaelis–Menten equation $[v = k_{ATPase}/(1 + K_{0.5}/[ATP]^n])$. Fluorescence based protein degradation assays were performed at 37°C in a 384-well black plate (Corning) using a SpectraMax M5 plate reader (ex = 467 nm; em = 511 nm) with 1 μ M ^{cchex}AFG3L2 or its variants and 20 μ M ^{SF}GFP-10/11^{A226G}- β 20 in the buffer containing 25 mM HEPES-KOH, pH 7.5, 100 mM KCl, 5 mM MgCl₂, 10% glycerol, 1 mM DTT, 2 mM ATP, 7.5 mM phosphoenolpyruvate, and 18.8 U ml⁻¹ pyruvate kinase (Key Resources Table). Initial cleavage rates were determined by measuring loss of 511 nm fluorescence over early linear time points. Fluorogenic peptide cleavage assays were performed at 37°C with 1 µM ^{core}AFG3L2^{WB} or its variants and 50 µM peptide (Leu-(3-NO2-Tyr)-Phe-Gly-(Lys-Abz)) (GenScript) (Key Resources Table) in a 384-well black plate using SpectraMax M5 plate reader (ex = 320 nm; em = 420 nm). The reactions were performed in the buffer containing 25 mM HEPES-KOH, pH 7.5, 100 mM KCl, 5 mM MgCl₂, 1 mM DTT, and 10% glycerol. Initial peptide cleavage rates were calculated from the loss of 420 nm fluorescence over early linear time points. Kaleidagraph (Synergy Software; Key Resources Table) was used to generate the ATPase Michaelis-Menten plot and related kinetic data shown in Figure S4F. Prism (GraphPad Software) was used for data presentation for all the other biochemical data (Key Resources Table).

Size Exclusion Chromatography (SEC) assay

For determination of SEC profiles, one liter of *E.coli* culture containing ^{core}AFG3L2^{WE/PI} or its variants were expressed and purified following the procedure described above for use in biochemical characterization prior to SEC. Proteins were applied to a Superdex 200 10/300 GL Increase column equilibrated with buffer containing 25 mM HEPES-HCI (pH 7.5),100 mM KCI, 10% glycerol, and 1 mM DTT. Elution profiles compared against molecular weight standards to determine the ratio of assembled hexameric species to disassembled species for each ^{core}AFG3L2^{WB/PI} variant. MATLAB (MathWorks) was used to present the data (Key Resources Table).

Sample preparation for electron microscopy

For cryo-EM structure determination, the ^{core}AFG3L2^{WB/PI} construct was incubated on ice for 5 min in 20mM Tris pH 8, 100mM NaCl, 5mM MgCl₂, 1mM DTT, 1mM AMPPNP, 1% glycerol and 0.05% Lauryl Maltose Neopentyl Glycol (LMNG, Anatrace). Glycerol and

LMNG were added to the buffer to help reduce the preferential orientation of the AFG3L2 particles in vitrified ice. 3 μ l of the sample at 2 mg/ml were applied to 300 mesh UltrAuFoil Holey Gold Films R1.2/1.3 (Quantifoil) that had been previously plasma cleaned in a 75% argon / 25% oxygen atmosphere at 15 Watts for 6 s using a Solarus plasma cleaner (Gatan, Inc). The grids were loaded into a Vitrobot (ThermoFisher) with an environment chamber at a temperature of 4°C and 100% humidity. Grids were blotted for 3 s with Whatman No.1 filter paper and plunged into a liquid ethane slurry.

Electron microscopy data acquisition

Cryo-EM data were collected on a ThermoFisher Talos Arctica transmission electron microscope (TEM) operating at 200keV, which was aligned as previously described (Herzik et al., 2017). Dose-fractionated movies were collected using a Gatan K2 Summit direct electron detector operating in electron counting mode, saving 30 frames during a 7 s exposure. At an exposure rate of 4.3 e⁻/pixel, this resulted in a cumulative exposure of 40 e⁻/Å². The Leginon data collection software (Suloway et al., 2005) (Key Resources Table) was used to collect 5,707 micrographs by moving to the center of four holes and image shifting to acquire four exposures at 36,000x nominal magnification (1.15 Å/pixel at the specimen level), with a nominal defocus range of -0.8 to $-1.8 \mu m$.

Image processing

The Appion image processing workflow (Lander et al., 2009) was used to perform real-time image pre-processing during cryo-EM data collection (Key Resources Table). Micrograph frames were aligned using MotionCorr2 (Zheng et al., 2017) and CTF parameters were estimated with CTFFind4 (Rohou and Grigorieff, 2015) (Key Resources Table). Only micrographs with Appion confidence values above 95% were further processed. A small subset of ~20,000 particles were selected with the FindEM template-based particle picker (Roseman, 2004) (Key Resources Table), using the negative stain 2D classes as templates. This subset of particles was extracted using an unbinned box size of 256 pixels, and binned by a factor of four for 2D classification using RELION 1.4 (Scheres, 2012) (Key Resources Table). The resulting class averages were used as templates to select particles using FindEM, yielding 4,541,491 coordinates for putative particle.

Relion 3.0 (Zivanov et al., 2018) (Key Resources Table) was used for all the remaining processing steps (Figure S1B). Particles were extracted using an unbinned box size of 160 pixels and binned by a factor of four for 2D classification. The resulting class averages showed a preferred hexameric view of the complex, so only the particles contributing to one of these hexameric classes were retained for subsequent processing steps. All other particles contributing to 2D classes containing well-defined secondary structural elements were also selected for 3D analysis. A total of 2,901,805 particles were extracted (binned by two, box size 80 pixels) and classified into five classes using the scaled and low-pass filtered cryo-EM structure of yeast YME1 (EMDB-7023) (Puchades et al., 2017) as an initial model and a regularization parameter of eight. The 1,129,437 particles contributing to the three best 3D class averages containing well-defined structural features were extracted with a box size of 240 pixels using centered coordinates. These particles were refined to a resolution of \sim 3.2 Å resolution, although the observable structural features were not consistent with this reported resolution, and were not sufficiently resolved for atomic modeling.

We next performed CTF refinement and beam tilt estimation (estimated beam tilt x = -0.25, beam tilt y = 0.07), and used these estimates to re-refine the particle stack, which yielded a structure with a reported resolution of \sim 3.0 Å. However, this reconstruction still appeared to suffer from issues with flexibility and misalignment, and did not contain structural features that are consistent with 3.0 Å cryo-EM density. Suspecting that these apparent misalignments may be due to subtle motions of the ATPase and protease rings relative to one another, we next performed a multi-body refinement of the AFG3L2 hexamer using three masked regions: the c6-symmetric protease ring, the four most stable ATPase domains (subunits B-E), and the two remaining ATPase domains for which the cryo-EM density was poorly resolved (subunits A,F). While these two flexible domains were not improved by the multi-body refinement approach and are reported at \sim 5 Å resolution, the observable details of the protease and four stable ATPase domains improved substantially. The reported resolutions for the ATPase and protease domains are \sim 3.0 Å and \sim 2.9 Å, respectively, by FSC 0.143.

Local resolution estimation using the "blocres" function in the Bsoft package (Heymann, 2018) indicates that there are regions within the reconstructions that are resolved to better than the FSC-reported resolutions. However, we do not observe EM density corresponding to ordered water molecules, which should be visible at better than 2.9 Å resolution so we suspect that the reported FSC-based resolutions are slightly inflated, possibly due to the presence of preferred views in the final reconstruction (Figure S1D). The individual reconstructions output from the multi-body refinement were individually sharpened and low-pass filtered (Table S2), and a composite map was generated to facilitate atomic model building using the "vop max" function in UCSF Chimera (Goddard et al., 2007).

Atomic model building and refinement

A homology model was generated using the structure of a subunit of YME1 (PDB ID: 6AZ0; Key Resources Table) as a starting point. Six copies of this atomic model were generated and each split into the three domains and rigid body fit into each subunit using the "fit in map" function in UCSF Chimera (Goddard et al., 2007). The ATPase domains of the apo and ATP1 subunits (subunits F and A, respectively) were not further processed as the quality of the density for these domains did not allow for confident atomic modeling, and are included in the deposited model only as a C α trace. The homology model for the rest of the hexamer, including nucleotides and coordinating metals, was adjusted using the COOT software package (Emsley and Cowtan, 2004), and then real-space refined

with rigid body fitting and simulated annealing using the PHENIX package (Afonine et al., 2012) (Key Resources Table). This refined model was used as input for a multi-model-generating pipeline (Herzik et al., 2019) that aided in assessing the quality of the model and the map for mechanistic interpretation (Figure S1F). Briefly, the refined model and the map were used to generate 200 models in Rosetta, and the top ten scoring models were selected for further refinement in Phenix. The per-residue $C\alpha$ root mean square deviation (RMSD) of top ten models was calculated and used to identify regions with poor model convergence. These regions were inspected and re-modeled and re-refined. Regions of the map with poor convergence either had the side-chains were truncated to the C β or removed entirely from the model.

UCSF Chimera (Goddard et al., 2007) was used to generate the figures (Key Resources Table).

Cell Culture and Mitochondrial isolation

HEK293T cells (Key Resources Table) were cultured in DMEM (Cellgro) supplemented with 10% fetal bovine serum (Cellgro), 1% penicillin/streptavidin (GIBCO) and 1% L-glutamine (Cellgro) at 37°C (5% CO₂). Cells were transiently transfected with pcDNA3.1 vector expressing C-terminally Flag-tagged AFG3L2 (GenScript) with the indicated single-point mutations (Key Resources Table). After 36h, mitochondria were isolated from cells as previously reported (Haynes et al., 2010).

SDS- and BN-PAGE analysis

Freshly isolated mitochondria were lysed in SDS (20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton supplemented with EDTA-free protease inhibitors (Roche)) or BN-Lysis buffer (20 mM Tris pH 7.5, 10% w/v glycerol, 50 mM NaCl, 0.1 mM EDTA, and 1mM PMSF supplemented with 1% n-dodecyl-β-D-maltoside). Samples were normalized by total protein concentration using Bio-Rad protein quantification. For SDS-PAGE, lysates were separated on 10% acrylamide gels and transferred onto nitrocellulose membranes (Bio-Rad) for immunoblotting. Following incubation with primary antibodies, membranes were incubated with IR-labeled secondary antibodies (Li-COR Biosciences) and analyzed using the Odyssey Infrared Imaging System (Li-COR Biosciences). BN-PAGE samples were separated on 4%–16% polyacrylamide gels, and western blotted as described (Geissler et al., 2002). Primary antibodies: anti-AFG3L2 (Genetex, 1:1000 dilution), anti-Flag (M2 Flag, Sigma, 1:1000 dilution), anti-Tubulin (Sigma, 1:10000 dilution) (Key Resources Table).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical details of all experiments can be found in the relevant figure legends. The biochemical data reflect the average of at least three independent experiments, and the error bars are the standard deviations generated from each group of data. Student's two-tailed t test were performed to indicate the statistical significance of our data. Statistical details of all experiments can be found in the relevant figure legends.

DATA AND CODE AVAILABILITY

All the cryo-EM maps were deposited in the Electron Microscopy Data Bank under accession code EMD-0552. The associated atomic coordinates were deposited into the Protein Data Bank with accession code 6NYY.

Molecular Cell, Volume 75


Supplemental Information


Unique Structural Features of the Mitochondrial

AAA+ Protease AFG3L2 Reveal the Molecular Basis

for Activity in Health and Disease

Cristina Puchades, Bojian Ding, Albert Song, R. Luke Wiseman, Gabriel C. Lander, and Steven E. Glynn







A. Representative motion-corrected, dose-weighted cryo-EM micrograph of vitrified substrate-bound $^{core}AFG3L2^{WB/PI}$. **B.** RELION processing scheme used to determine the 3D reconstruction of AFG3L2. Details provided in the Methods. **C.** Local resolution were calculated using the Bsoft package (Heymann, 2018), showing that the final EM-density of $^{core}AFG3L2^{WB/PI}$ shows the resolution varies from 3.1 Å at the core of the complex to 3.5 Å for the built regions. **D.** The distribution of the Euler angles assigned to the particles in the final consensus reconstruction. Note the presence of some preferred views, which may inflate the reported FSC-based resolution. **E.** FSC plots of the unmasked and masked reconstructions of the three components refined through multibody analysis in RELION. The FSC calculated using the composite map and the atomic model is also shown (dashed grey line). **F.** Histogram of the per-residue Ca RMSD values calculated from the top ten refined atomic models with the mean per-residue Ca RMSD value shown as a black vertical bar (Herzik et al., 2018). Inset is a worm representation of the atomic model, colored according to the per-residue Ca RMSD values depicted in the histogram.

Α

A




Figure S2. Conservation of the hand-over-hand mechanism for substrate translocation across eukaryotes. Related to Figure 1.

A. Individual protomers of yeast i-AAA protease YME1 (top) and human m-AAA protease AFG3L2 (bottom) shown side by side, aligned with the protease domain in the same orientation. The cryo-EM density is shown as a transparent grey isosurface. For each subunit, the relative orientation between the ATPase and protease domains is almost identical in YME1 and AFG3L2. The core mechanistic features of **B.** AFG3L2 and **C.** YME1 are essentially indistinguishable. Top left, the conserved pore-loop 1 aromatic residue intercalates into the substrate backbone every two amino acids. Top right, the nucleotide binding features characteristic of P-loop ATPases are shown for the ATP2 and ADP subunits with the cryo-EM density corresponding to nucleotide shown in mesh. Bottom, the ATP-bound nucleotide-binding pocket reveals conservation of all the elements involved in the ATP hydrolysis cycle and the allosteric transmission of the nucleotide-dependent conformational changes to the pore-loops.

Δ		^{core} AFG3L2 N-terminus of the atomic	
Cata	alytic SI	core construct model of AFG3L2 non-conserved N-terminus	
Paraplegin		SYKRTGFFGNALYSVGMTAVGLAILWYVFRLAGMTGREGGFSAFNQLKMARFTI	P-loop
AFG3L2		VYIAESD-GSFLLSMLPTVLIIAFLLYTIRRGPAGIGRTGRGMGGLFSVGETTAKV	β2 and β3-strands Phenylalanines
Ytal0 Ytal2	62% 63%	KYIERSSPFTFLFPFLPTIILLGGLYFITRKINSSPPNANGGGGGGLGGMFNVGKSRAKL LYVQEGNWAKAMFQILPTVLMIAGIIWLTRRSAQAAGGSRGGIFGLSRSKAKK	Pore-loop 1
YME1L	44%	QKTNDSLRRTRLILFVLLLFGIYGLLKNPFLSVRFRTTTGLDSAV	Water activating residue
YME1	43%	ESTFTVVSRWVKWLLVFGILTYSFSEGFKYITENTTLLKSSEVADKS	Pore-loop 2
EColiFtsH	47%	EEPSLLASIFISWFPMLLLIGVWIFFMRQMQGGGGKGAMSFGKSKARM	ISS motif
De ser la seta		Walker A	Arginine fingers
Paraplegin AFG3L2		VDGKMGKGVSFKDVAGMHEAKLEVREFVDYLKSPERFLQLGAKVPKGALLLGPPGCGKTL LKDEIDVKFKDVAGCEEAKLEIMEFVNFLKNPKQYQDLGAKIPKGAILTGPPGTGKTL	Residues mutated in disease
Yta10		FNKETDIKISFKNVAGCDEAKQEIMEFVHFLKNPGKYTKLGAKIPRGAILSGPPGTGKTL	
Yta12		FNTETDVKIKFKDVAGCDEAKEEIMEFVSFLKEPSRYEKMGAKIPRGAILSGPPGTGKTL	
YME1L YME1		- DPVQMKNVTFEHVKGVEEAKQELQEVVEFLKNPQKFTILGGKLPKGILLVGPPGTGKTL - VDVAKTNVKFDDVCGCDEARAELEEIVDFLKDPTKYESLGGKLPKGVLLTGPPGTGKTL	
EColiFtsH		-LTEDQIKTTFADVAGCDEAKEEVAELVEYLREPSRFQKLGGKIPKGVLMVGPPGTGKTL	
		.* .* * .**: *: *.* :*: : :*.*:*: :: *******	
Paraplegin		Pore-loop 1 Walker B LAKAVATEAQVPFLAMAGPEFVEVIGGLGAARVRSLFKEARARAPCIVYIDE	
AFG3L2		LAKATAGEANVPFITVSGSEFLEMFVGVGPARVRDLFALARKNAPCILFIDEIDAVGRKR	
Yta10		LAKATAGEANVP <mark>F</mark> LSVSGSEFVEM <mark>FVG</mark> VGASRVRDLFTQARSMAPSIIFIDE	
Yta12 YME1L		LAKATAGEAGVPFYFVSGSEFVEMFVGVGAARVRDLFKTARENAPSIVFIDEIDAIGKAR LARAVAGEADVPFYYASGSEFDEMFVGVGASRIRNLFREAKANAPCVIFIDELDSVGGKR	
YME1		LARATAGEAGVDFFIIASGSEFDEWFVGVGASKIRNLFREARANAFCVIFIDELDSVGGRR	
EColiFtsH		LAKAIAGEAKVP <mark>F</mark> FTISGSDFVEM <mark>FVG</mark> VGASRVRDMFEQAKKAAPCII <mark>F</mark> ID <mark>E</mark> IDAVGRQR	
		**:* * ** * * :* :* :* *: *:* *: *: *: *	
Paraplegin		STT-MSGFSNTEEEDTLNOLLVEMDGMGTTDHVIVLASTNRADILDGALMRPGRLDRHVF	
AFG3L2		GRG-NFGG-QSEQENTINQLLVEMDGFNTTTNVVILAGTNRPDILDPALLRPGFFDRQIF	
Yta10		GKGGALGGANDERE <mark>ATLN</mark> QLLVEMDGFTTSDQVVVLAGTNRPDVLDNALMRPG <mark>R</mark> FDRHIQ	
Ytal2 YME1L		QKG-NFSGANDERENTLNQMLVEMDGFTPADHVVVLAGTNRPDILDKALLRPGFFDRHIN IESPMHPYSROTINQLLAEMDGFKPNEGVIIIGATNFPEALDNALIRPGFFDMQVT	
YME1		NPKDQAYAKQTLNQLLXELDGFSQTSGIIIIGATNFPEALDKALTRPGRFDKVVN	
EColiFtsH		GAGLGGGHDERE <mark>OTLN</mark> QMLVEMDGFEGNEGIIVIAATNRPDVLDPALL <mark>RPGR</mark> FDRQVV	
		· · · · · · · · · · · · · · · · · · ·	
Paraplegin		IDLPTLOERREIFEOHLKSLKLTOSSTFYSORLAELTPGFSGADIANICNEAALHA	
AFG3L2		IGPPDIKGRASIFKVHLRPLKLDSTLEKDKLARKLASLTPGFSGADVANVCNEAALIA	
Yta10		IDSPDVNGRQQIYLVHLKRLNLDPLLTDDMNNLSGKLATLTPGFTGADIANACNEAALIA	
Ytal2 YME1L		IDKPELEGRKAIFAVHLHHLKLAGEIFDLKNRLAALTPGFSGADIANVCNEAALIA VPRPDVKGRTEILKWYLNKIKFDQSVDPEIIARGTVGFSGAELENLVNQAALKA	
YME1		VDLPDVRGRADILKHHMKKITLADNVDPTIIARGTPGLSGAELANLVNQAAVYA	
EColiFtsH		VGLPDVRGREQILKVHMRRVPLAPDIDAAIIARGTPGFSGADLANLVNEAALFA : * :. * * ::::: :* * *::**:: * *:**: *	
B Cat	talytic SI	core Protease	
D	SI	core Protease	
Paraplegin AFG3L2	SI 54%	CORE Glycine linker Protease areghtsvhtlnFeyavervlagtaktkskilskeeQtvvRHesGlavvgmlehteavm ARHLSDSIN0KHFEQATERVICGLEKKTVVLOPEEKKIVNFHESGLAVAGMVLEHADPLL]	Residues mutated in disease
Paraplegin AFG3L2 Yta10	SI 54% 62%	Core Ciycine linker C	Residues mutated in disease
Paraplegin AFG3L2	SI 54% 62% 63%	CORE Glycine linker Protease areghtsvhtlnFeyavervlagtaktkskilskeeQtvvRHesGlavvgmlehteavm ARHLSDSIN0KHFEQATERVICGLEKKTVVLOPEEKKIVNFHESGLAVAGmvLEHADPLL]	Putative substrate interacting
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1	SI 54% 62% 63% 44% 43%	Core Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQKVVVFHESGHALVGWMLEHTEAVM ARHLSDSINOKHFEQAIERVLIGGLEKKTOVLOPEEKKSVN, HEAGHAVGWFLEHADPLL ARHNDPYITIHHFEQAIERVLIGGUEKKTRVLSKEEKRSVN, HEAGHAVGWFLKYADPLL ARSDEDAVKLINHFEQAIERVIGGUEKKSKLLSPEEKKVV, HEAGHAVGWFLKYADPLL AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITYHESGHAIIAYYTKDAMPIN CQKNAVSVDSHFEWAKDKILMGPERSVEIDNKNKTITYHESGHAIAAKATPFLY	
Paraplegin AFG3L2 Yta10 Yta12 YME1L	SI 54% 62% 63% 44% 43%	core Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEORVYL FHSGIALGWMLEHTEAVM ARHLSDSINOKHFEQAIERVIGGLEKKTOVLOPEEKKTVN FHSGIALGWMLEHTEAVM ARHLSDSINOKHFEQAIERVIGGLEKKTOVLOPEEKKTVN FHSGIAVGGWPLEKADPLL ARNDEVITITHHFEQAIERVIGGLEKKTOVLOPEEKKTVN FHSGIAVGGWPLEKADPLL ARSDEDAVKLNHFEQAIERVIGGUEKKTOVLOPEEKKTVN FHSGIAVGGWPLKYADPLL AVGGKEWVTKKELEFSKDKILMGGERKSVEJIDNKIKTITY FHSGIAITAYTKDAPFIN CQKNAVSVDMSHFEWARDKILMGGERKSWMTEAQKEST FHSGIAIIGKLVPEHDPVH	Putative substrate interacting residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1	SI 54% 62% 63% 44% 43%	Core Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQKVVVFHESGHALVGWMLEHTEAVM ARHLSDSINOKHFEQAIERVLIGGLEKKTOVLOPEEKKSVN, HEAGHAVGWFLEHADPLL ARHNDPYITIHHFEQAIERVLIGGUEKKTRVLSKEEKRSVN, HEAGHAVGWFLKYADPLL ARSDEDAVKLINHFEQAIERVIGGUEKKSKLLSPEEKKVV, HEAGHAVGWFLKYADPLL AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITYHESGHAIIAYYTKDAMPIN CQKNAVSVDSHFEWAKDKILMGPERSVEIDNKNKTITYHESGHAIAAKATPFLY	Putative substrate interacting residues Glycine linker
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1	SI 54% 62% 63% 44% 43%	COFE Protease active site AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEQKVUT FHESGIALVGWMLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVUT FHEAGIALVGWLKADPLL ARSDEDAVKLINFEQAIERVLGLEKKTOVLOPEEKKVUT HHEAGIALVGWLKADPLL ANSDEDAVKLINFEQAIERVLGLEKKTVLTDARKKSVUT HHEAGIALAVGWLKADPLL AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVTMADFIN CQKNAVSVDMSHFEMAKDKILMGAERKTMVLTDARKATAFIHEAGIAIMAXTNOATPLY ARGNKRVVSWFEFKAKDKILMGAERKTMVLTDARKATAFIHEAGIAIMAXTNOATPLY ARGNKRVVSWFEFEKAKDKILMGAERKTMVLTDARKATAFIHEAGIAIMAXTNOATPLY AKGNKRVSMVFEFEKAKDKILMGAERKTMVLTDARKATAFIHEAGIAIMAXTNOATPLY AKGNKRVSMFEFEKAKDKILMGAERKTMVLTDARKATAFIHEAGIAIMAXTNOATPLY AKGNKRVSNFFEKAKDKILMGAERKTMVLTDARKATAFIHEAGIAISTIN CVKSITPRTNAALGFAQMLP-RDOHLETKEQLFERMCMALGGRASEALSFNEVTSGAQD	Putative substrate interacting residues Glycine linker Protease active site
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2	SI 54% 62% 63% 44% 43%	COFE Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQKVVR HESGIALVGWMLEHTEAVM ARHLSDSINOKHFEQAIERVIGGLEKTOVLOPEEKKIVN HEGGIAVGGWFLEXAPPLL ARSDEDAVKLNHFEQAIERVIGGLEKKTRVLSKEEKKSVN HEAGIAVGWFLEXAPPLL ARSDEDAVKLNHFEQAIERVIGGLEKKTVLTDAARKSTN HEAGIALAVGWFLEXAPPLL AVDGKEWVTMKELEFSKDKILMGGERKSVEIDNKIKTITN HEAGIAILAYTTKDAMPIN COKINAVSVDMSHFEMAKDKILMGGERKSVEIDNKIKTITN HEAGIAILGUVEHDPVH . : :: :: :: : : : : : : : : : : : : :	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Ytal0	SI 54% 62% 63% 44% 43%	COPE Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQRVVL ACTAKKSKILSKEEQRVVL ACTAKSKILSKEEQRVVL PHEAGIAVGWYLEHEADPLL ARHNDPYTITIHHFEQAIERVIAGLEKKTOVLOPEEKKTVN HEAGIAVGWYLEHADPLL ARNNDPYTITIHHFEQAIERVIAGLEKKTOVLOPEEKKTVN HEAGIAVGWYLEHADPLL ARSDEDAVKLNHFEQAIERVIAGLEKKTOVLOPEEKKTVN HEAGIAVGWYLEHADPLL ARSDEDAVKLNHFEQAIERVIAGLEKKTOVLOPEEKKTVN HEAGIAVGWYLEHADPLL ARSDEDAVKLNHFEQAIERVIAGEKKTVNUTARAKATTITNESGIAITAYTKDAPPLI AVDGKENVTMKELEFSKDKILMGERKSVEIDNKIKTITN CONNAVSUNSHFEKAKARDKILMGERKSTNVUTEAQKESTAYHEAGIAINAKTNOATPLY ARGNKRVVSMVEFEKAKDKILMGGERKSNVHTEAQKESTAYHEAGIAIIGRLVPEHDPVH . : KVSITPRTNAALGFAQMLP-ROPULTKEQLEPRMCMALGGRASEALSFN-EVTSGAQD KVSITPRGQGALGYAQYLP-ROPULTKEQLEPRMKINALGGRVSEELIFFGRITTGAQD KVSITPRGQGALGYAQYLP-POQULIFSEQFKHRMIMALGGRVSEELHFP-SVSTGAAHD	Putative substrate interacting residues Glycine linker Protease active site
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2	SI 54% 62% 63% 44% 43%	COFE Protease active site AREGHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQKVVR HESGIALVGWMLEHTEAVM ARHLSDSINOKHFEQAIERVIGGLEKTOVLOPEEKKIVN HEGGIAVGGWFLEXAPPLL ARSDEDAVKLNHFEQAIERVIGGLEKKTRVLSKEEKKSVN HEAGIAVGWFLEXAPPLL ARSDEDAVKLNHFEQAIERVIGGLEKKTVLTDAARKSTN HEAGIALAVGWFLEXAPPLL AVDGKEWVTMKELEFSKDKILMGGERKSVEIDNKIKTITN HEAGIAILAYTTKDAMPIN COKINAVSVDMSHFEMAKDKILMGGERKSVEIDNKIKTITN HEAGIAILGUVEHDPVH . : :: :: :: : : : : : : : : : : : : :	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1	SI 54% 62% 63% 44% 43%	COPE Protease active site AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEQRVVIFHEGGIAVGWHLEHTEAVM ARHLSDSINQKHFEQAIERVIGGLEKKTOVLOPEEKKTVNFHEGGIAVGWFLKADPLL ARHLSDSINQKHFEQAIERVIGGLEKKTOVLOPEEKKTVNFHEGGIAVGWFLKADPLL ARHLSDSINQKHFEQAIERVIGGLEKKTOVLOPEEKKTVNFHEGGIAVGWFLKADPLL ARSDEDAVKLINHFEQAIERVIGGLEKKTOVLOPEEKKTVNFHEGGIAVGWFLKADPLL ARSDEDAVKLINHFEQAIERVIGVERKSKLSPEEKKVVNFHEGGIAVGWFLKADPLL ARSDEDAVKLINHFEQAIERVIGVERKSLSPEEKKTVNFHEGGIAIGAVGWFLKADPLL ARSDEDAVKNFHEGAIERVIGVERKSLLSPEEKKVVNFHEGGIAIGAVGWFLKADPLL ARSDEDAVKNHFEQAERSVIGVERKSLLSPEEKKVVNFHEGGIAIGAVGWFLKADPLY AGURRYVSNVEFEKAKDKILMGAERKSVVTHAQKESTNFHEAGIAIIGRUVERPLY ARGURRYVSNVEFEKAKDKILMGAERKSVVTELGQKESTNFHEAGIAIIGRUVERPLY STIFTRTNAALGFAQMLP-RDOHLFTKEQLFERMCMALGGRASEALSFNEVTSGADD KVSIIPRGGGLGGAQYLP-RDOHLFTKEQLFERMCMALGGRVSEELIFFPSVTSGADD KVSIIPRGGGLGGAGYQLP-PODIFLIESEDFRHRMINALGGRVSEELIFFPSVTSGADD KVSIIPRGGGLGAGYQQLP-PODIFLIESEDFRHRMANLAGGRVSEELIFFPSVTSGADD KVSIIPRGGALGAQYQPLP-PODIFLIEQLAQMDVSMGGRVAEELIFGDHITGGASS KATILMPRGPL-LGHVSLLPENDRWNETRAQLLAQMDVMGGKAAEELIFGDHITGGASS KATILMPRGALGITGDHITGDPEMDKVDITKRECQARLDVCMGKAAEELIFGDHITGGASS	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 EColiFtsH Paraplegin AFG3L2 Ytal0 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 Ytal2 YME1	SI 54% 62% 63% 44% 43%	COTE Protease active site AREGHTSVHTLNFETAVERVLAGTAKSKILSKEDGVV FHEGGIALVGWHLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKSKILSKEDGVV FHEAGIAVGGWFLKYADPLL ARNDEDAVKLINFEQAIERVLGGLEKKTOVLOPEEKKTV FHEAGIAVGGWFLKYADPLL ARSDEDAVKLINFEQAIERVLGGLEKKTVLDARKSKILSPEEKKVV FHEAGIAVGGWFLKYADPLL AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVTWADPLI AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVTWADPLI AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVTWADPLI AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVTWADPLI AVDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAINAVTWOAPPIN CQKNAVSVDNSHFENAKDKILMGAERKTMVLTDAARKATNHEAGIAINAVTTNATPLY ARGNKRVVSWEFEKAKDKILMGAERKTMVLTDAARKATNHEAGIAIIGINTENDPVH . : :*****: KVSITPRTNAALGFAQMLP-RDOHLETKEQLFERMCMALGGRVSEELFFGSTTSGADD KVSIIPRGQALGYAQTUP-EOPULISEOFRHRMIMALGGRVSEELHFPSVTSGAND KVSIIPRGQALGYAQTUP-GDIFLITEQQLKDRMTMSLGGRVSEELHFPSVTSGADD KVSIIPRGQALGYAQTP-GDIFLITEQQLKDRMTMSLGGRVSEELHFPSVTSGADD KVSIIPRGQALGYAQTP-EDPHLETKEQLARLDAVDVSMGGRVAELLIFGTDHITTGSSS KATILPRGRA-LGVTFLPEGDAISASRQKLESQISTLYGGRIAEELIYGEMDATSGGSS KVTIIPRGRA-LGVTFLPEEDAISASRQKLESQISTLYGGRIAEELIYGEMDATSGGSS	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1	SI 54% 62% 63% 44% 43%	core Protesse active site AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVVDFHEGGIALVGWHLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEDGVVDFHEGGIALVGWHLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEDKVVDFHEGGIALVGWHLEHTEAVM ARHLSDSINOKHFEQAIERVLGEKKTOVLOPEEKKTVNFHEGGIALVGWHLEHTEAVM ARSDEDAVKLINFFQAIERVLGEKKTOVLOPEEKKTVNFHEGGIALVGWHLEVTAPPLL ARSDEDAVKINFFQAIERVLGEKKTOVLOPEEKKTVNFHEGGIALVGWHLEVAPPLL ARSDEDAVKUNFFGAIERVLGEKKSVNFHEGGIALVGWHLEVAPPLL ARGURRVVSWLFFGAIERVLGERKSVESUNKIKTITNHESGIAILAVTWAPPLL ARGURRVVSWFFFGAKAKDKINGGERKSVMTEDGKESTNFHEGGIALAUGAVGWHLEVAPPLL ARGURRVVSWFFFGALAGVLINGGERKSVMTEDGKESTNFHEGGIALIGENVFFHPVH . . . KVSIIPRGOGALGYAQYLP-RDOHLFTKEQLFERMCMALGGRSEELHFP-SVTSGADD KVSIIPRGOGALGYAQYLP-PEQVITKEEDEFNRHIMALGGRVSEELHFP-SVTSGADD KVSIIPRGOGALGYAQYLP-PEDVILSEEDFRHRVINKSLGGRVVSMGGRAUELIFFOHITTGASS KATLIPRGT-LGHVSLLPENDRWNFTRAQLAQHVSMGGRVAELIFYCHHTTSGGSS KVSIIPRGOGALGYAQYLP-EDDIALTKESQALAQUVSMGGRVAELIFYCHHTTGSGSS KVTIIPRGRA-LGYTFLPEDGAISASRQKLESQISTLYGGRLAEELIFYCHHTTGSGSS	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L YME1L YME1L YME1L Paraplegin	SI 54% 62% 63% 44% 43%	COME Protests AREGHTSVHTLNFFEAVERVLAGTAKKSKILSKEEQKVV FRAGIAVGWYLEHTEAVM AREGHTSVHTLNFFEAVERVLAGTAKKSKILSKEEQKVV FRAGIAVGWYLEHTEAVM ARHNDYYTTHHFEQAIERVIGGLEKKTOVLOPEEKKVV FRAGIAVGWYLEHTEAVM ARNODYYTTHHFEQAIERVIGGLEKKTOVLOPEEKKVV FRAGIAVGWYLEHTEAVM ARSDEDAVKLINHFEQAIERVIGGLEKKTOVLOPEEKKVV FRAGIAVGWYLEHTEAVM ARNODYYTTHHFEQAIERVIGGLEKKTOVLOPEEKKVV FRAGIAVGWYLEHADPLL ARSDEDAVKLINHFEQAIERVIGGEKKSTULSPEEKKVV FRAGIAVGWYLEHADPLL ANCOMYLEHADPL ARSDEDAVKLINHFEQAIERVIGGEKKSKLSPEEKKVV FRAGIAVGWYLEHADPL ANCOMYLEHADPL AVDKERVVDWSHFEKAKDKILMGERKSVLSPEEKKVV FRAGIAVGWYLEHADPL ANCOMYLEHADPL AVDKERVVDWSHFEKAKDKILMGERKSVLSPEEKKVV FRAGIAVGWYLEHADPL ANCOMYLEHADPL AVDKERVVDWSHFEKAKDKILMGERKSVLSPEEKKVV FRAGIAVGWYLEHADPL ANCOMYLEHADPL AVDKERVVDWSHFFEKAKDKILMGERKSVLSPEEKKVVFTAGASSEST FYFGE-STITGADD ANCOMYLEHADPL XVSIIFRGGALGYAQYLP-PDQYLISEEQFRHRMIMALGGRVSEELHFFG-SVTSGADD KVSIIFRGQGALGYAQYLP-PDQYLISEEQFRHRMIMALGGRVSEELHFFG-SVTSGADD KVSIIFRGQALGYAQYLP-GDIFLLTEQQLKNRMTMSLGGRVSEELHFFG-SVTSGADD KVSIIFRGQGALGYAQYLP-GDIFLLTEQQLKNRMTMSLGGRVSEELHFFG-SVTSGADD KVSIIFRGRA-LGUTFFLEHEDKINFTRAGLISASRUKLSQISTLYGGRLAELIFGTDHTTGGSS XTILPRGRA-LGUTFFLEHEGDAISASRUKLSQISTLYGGRLAELIFGTDHTTGGSS KVSIIFRGUGALGYAQYLP-GDIFLTEGQLSASKLSSGISTLYGGRLAELIFTGHTAGASS XTILPRGRA-LGUTFFLEHEGDAISASRUKLSGISTLYGGRLAELIFTGHTAGASS KVSIIFRGUGALGYAQYLP-GDIFLTEGQLFTAVGTAALLARUKUN	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2	SI 54% 62% 63% 44% 43%	COPE Protesse City and City and Cit	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin <u>AFG3L2</u> Yta10 Yta12 YHE1L YHE1L ECOliFtsH <u>AFG3L2</u> Yta10 Yta12 YHE1L ECOliFtsH <u>Paraplegin</u> <u>AFG3L2</u> Yta10 Yta12 YHE1L YHE1L YHE1L YHE1L YHE12 Y	SI 54% 62% 63% 44% 43%	COTE Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVVD FHESGIAUGWMLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKSV VFHEAGIAVGWLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKKV VFHEAGIAVGWLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKKV VFHEAGIAVGWLEHTEAVM ARSDEDAVGULAGTAKKSKILSKEEKKV VFHEAGIAVGWLEHTEAVM ARSDEDAVGULAGTAKSKILSKEEKKSV VFHEAGIAVGWLEKADPLL ARSDEDAVGULAGTAKSKILSKEEKKSV VFHEAGIAVGWLEKADPLL ARSDEDAVGULAGTAKSKILSPECKKV VFHEAGIAVGWLEKADPLL ANDGKEMVTHKELEFSKDKILMGPERSVEIDKINKTIT MESGIAIIAVGWLEKADPLL ANGUREMVTHKELEFSKDKILMGPERSVEIDKINKTIT MESGIAIIAVGWLEKADMPIN COKNAVSVDESKKADKI IMGGERKSWUTEDAGKSET MEAGIAINAKTNOATPLIV ARGUNEVSVUESKALSKIK IMGGERKSWUTEDAGKSET MEAGIAIIAGTAVGENTURPVH	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2	SI 54% 62% 63% 44% 43%	COPE Protesse City and City and Cit	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin <u>AFG3L2</u> Yta10 Yta12 YME1L YME1L Paraplegin <u>AFG3L2</u> Yta10 Yta12 YME1L Paraplegin <u>AFG3L2</u> YME1 ECOLIFTSH Paraplegin <u>AFG3L2</u> YME1 Paraplegin <u>AFG3L2</u> YME1 Paraplegin <u>AFG3L2</u> YME1 Paraplegin	SI 54% 62% 63% 44% 43%	COTE Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEDGVVDTPHESGIAUGWMLEHTEAVM ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVVDTPHEAGHAVAGWYLEHADPLEL ARHLSDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVVDTPHEAGHAVAGWYLEHADPLEL ARNDEPTITHHFEQAIERVLAGTAKKSKILSKEEKKVVDTPHEAGHAVAGWYLEHADPLEL ARSDEDAVGUME ARSDEDAVGUME ANDGKEMVTMKELEFSKDKILMGPERSVEIDNKNKTITNHESGIAIIAVYTKDAMPIN CQKINAVSVDISHFENAKDKILMGGERKSVEIDNKNKTITNHESGIAIIAVYTKDAMPIN CQKINAVSVDISHFENAKDKILMGGERKSVEIDNKNKTITNHESGIAIIAVYTKDAMPIN CQKINAVSVDISHKINGGEKSKNVTTEAGLAGRASEALSFNEVTSGADD KVSITPRTNAALGFAQMLP-RDOHLFTKEQLFERMCMALGGRVSEELHFFO-SVTSGADD KVSITPRQGALGYAQYLP-PEQYLIKEEOGRHRMIMALGGRVSEELHFFO-SVTSGADD KVSITPRQGALGYAQYLP-PEQYLIKEEOGRKMTMSLGGRVSEELHFFO-SVTSGADS KVSITPRGGALGYAQYLP-PEDIFLIEVOLDERKMTMSLGGRVSEELHFFO-SVTSGADS KVSITPRGGALGYAQYLP-EDIFLIEVOLDERKMTSKEGARLEUTGENTHTGSSS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGADS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGASS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGASS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGASS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGASS KVSITPRGGALGYAQYLP-EDIFTSFOLOLKUNTMSLGGRVSEELHFFO-SVTSGASS KVSITPRGGALGYAGYLPFEDATISSFOKLESSISTIYG	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 YME1L Paraplegin AFG3L2 Yta10 Yta12 Yta12 Yta12 Yta12 Yta12 Yta12 Yta13 Yta14 Yta14 Yta14 Yta14 Yta14 Yta15 Yta15 Yta15 Yta15 Yta15 Yta16 Yta16 Yta17 Yta16 Yta17 Yt	SI 54% 62% 63% 44% 43%	COTE Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEORV VI FHESGIALVGWILEHTEAVM ARARDETSVHTLNFETAVERVLAGTAKKSKILSKEORV VI FHESGIALVGWILEHTEAVM ARHNDPYTITIHHFEQATERVLAGTAKKSKILSKEEKRSV VI FHEAGIAVGWILEHTEAVM ARHNDPYTTIHHFEQATERVLAGTAKKSKILSKEEKRSV VI FHEAGIAVGWILEHTEAVM ARSDEDAVKLINHFEQATERVIAGUEKKTVUSKEEKRSV VI FHEAGIAVGWILEHTEAVM ARSDEDAVKLINHFEQATERVIAGUEKKTVUSKEEKRSV VI FHEAGIAVGWILEKTAPPLI ARSDEDAVKLINHFEQATERVIAGUEKKTVUSKEEKRSV VI FHEAGIAVGWILEKAAPPLI AVGKENVTMKELEFSKDKILMGGERKSVELDSKIKKTTT HESGIATIAVYTKDAPPLIN AVGKENVTMKELEFSKDKILMGGERKSVELDKIKKTTT HESGIATIAVYTKDAPPLIN AVGKENVTMKELEFSKDKILMGGERKSVENVUTDARKAT VI FHEAGIANIAMSTYTDATPLIY ARGNKRVVSMVEFEKAKDKILMGGERKSNVHTEAQKEST DYHEAGIATIAMSTYTDATPLIY ARGNKRVVSMVEFEKAKDKILMGGERKSNVHTEAQUKST DYHEAGIATIGMINKSTORAPINE KVSTIPRKGGLEGAQULP-PODULTKEQLERMKMINALGGRVSEELHFPSVTSGADD KVSTIPRGGGLEGAQYLP-PODULTKEQLERMKMINALGGRVSEELHFPSVTSGADD KVSTIPRGGALGYAQYLP-GDIPILITEQQLKDRMTMSLGGRVSEELHFPSVTSGADD KVSTIPRGRA-LGITTQLPENDKVDTKREQARLDVCMGGKIAEELIYGCDNTTSGCSS KATILPRGRA-LGITTQLPENDKVDTKREQARLDVCMGGKIAEELIYGCDNTSGCGS KVSTIPRGRA-LGITTGPPENDENTSOLOGUNDKINGSKIAEELIYGCDNTSGCSS KATILPRGRA-LGITTPLEEDDATASSEXCEGEDHVLEERTSSOLOGUNDHFARL DIKKVERTAASMVKOPG APGI'DET SFFEAGEGNFKV-NNFSSNETARTIDLVKS	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin <u>AFG3L2</u> Yta10 Yta12 YME1L YME1L Paraplegin <u>AFG3L2</u> Yta10 Yta12 YME1L Paraplegin <u>AFG3L2</u> YME1 ECOLIFTSH Paraplegin <u>AFG3L2</u> YME1 Paraplegin <u>AFG3L2</u> YME1 Paraplegin <u>AFG3L2</u> YME1 Paraplegin	SI 54% 62% 63% 44% 43%	COTO Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEORV VI FHESGIALVGWILEHTEAVM ARHENDYNTINFEGATERVILGGEKKTOVLOPEEKKY VI FHESGIALVGWILEHTEAVM ARHINDPYTTIHHFEQATERVILGGEKKTOVLOPEEKKY VI FHESGIALVGWILEHTEAVM ARHINDPYTTIHHFEQATERVILGGEKKTOVLOPEEKKY VI FHESGIALVGWILEHTEAVM ARKINDPYTTIHHFEQATERVILGGEKKTOVLOPEEKKY VI FHESGIALVGWILEHTEAVM ARSDEDAVKLINHFEQATERVILGGEKKTOVLOPEEKKY VI FHESGIALVGWILEHTEAPPLI ARSDEDAVKLINHFEQATERVILGGEKKSTULSPEEKKY VI FHEAGIAVGWILEHTEAPPLI ARSDEDAVKLINHFEQATERVILGGEKKSKILSPEEKKY VI FHEAGIAVGWILENAPPLI AND GKENVTMKELEFSKDK LIMGGEKRSVELDNKIKTIT MESGIATIAWSTNGAMPLIN AND GKENVTMKELEFSKDK LIMGGEKRSMVHTEAQKES TIMHEAGIANGGALAUKSMTPLY ARGNKRVVSMVEFEKAKDKI IMMGAERKSMVHTEAQKES TIMHEAGIANGENSELIFFGEVTSGADD KVSTIPROGALGYAQYLP-PDOULTKEOLFRMCMALGGRVSEELHFFGSVTSGADD KVSTIPROGGALGYAQYLP-PDOULTKEQLFRMCMALGGRVSEELHFFGSVTSGADD KVSTIPROGGALGYAQYLP-DOULTKEQLARUMVDSMGGRVEELHFFGSVTSGADD KVSTIPROGGALGYAQYLP-GDIFLITEQQLKNRMMSLGGRVSEELHFFGSVTSGADD KVSTIPROGGALGYAQYLP-GDIFLITEQQLKNRMTMSLGGRVSEELHFFG-SVTSGASD KVSTIPROGGALGYAQYLP-GDIFLITEQUENKENTELGUNCHGGKIAELIJEGDUNTSGGS KVSTIPROGGALGYAQYLP-GDIFLITEQUENKSMESTALFEGONT KVSTIPROGGALGYAQYLP-GDIFLITEGOLSON MARDEGUESTIGUT LURKVENGGEA-LGIFTOLPENDAKUDTKRECORTLOCKMARDKTEGGENT LURKVENGGEA-LGIFTOLPENDALSON	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YHE1L YME1 EColiFtsH Paraplegin AFG3L2 Ytal0 Ytal2 Ytal1 YHE1L YME1L Paraplegin AFG3L2 Ytal0 Ytal2 YHE1L YME1L Paraplegin AFG3L2 Ytal0 Ytal1 Paraplegin	SI 54% 62% 63% 44% 43%	COTO Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVVULPHESGIAUGWHLEHTAVM ARHLEDSINOKHEGATERVLAGTAKKSKILSKEDGVVULPHEAGIAVGWYLEHAPPLI ARNDEYTITIHHFEGATERVLAGTAKKSKILSKEEKRSVUTHEAGIAVGWYLEHAPPLI ARNDEYTITIHHFEGATERVLAGLEKKTOVLOPEEKKIVVTHEAGIAVGWYLEHAPPLI ARNDEYTTHHFEGATERVLAGLEKKTOVLOPEEKKIVTHEAGIAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTHEAGIAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTHEAGIAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTHEAGIAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTHEAGIAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTTAGKAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEEKKIVTTAGAVGWYLEHAPPLI ARSDEDAVKLINHFEGATERVLAGLEKKTOVLOPEKKIVTTAGAVGWAVGUNGKANAVGUNGUNGUNGHAVGUNGUNGHAVGUNGUNGHAVGUNGUNGUNGUNGUNGUNGUNGUNGUNGUNGUNGUNGUNG	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin <u>AFG3L2</u> Yta10 Yta12 YHE1L YHE1 ECOliFtsH Paraplegin <u>AFG3L2</u> Yta10 Yta12 YHE1L ECOliFtsH Paraplegin <u>AFG3L2</u> Yta10 Yta12 YHE1 ECOliFtsH Paraplegin <u>AFG3L2</u>	SI 54% 62% 63% 44% 43%	COTO Procession AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEDRVV FHEGGIAUGWALEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSKEEKSV VFHEGGIAUGWALEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSKEEKSV VFHEGGIAUGWALEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSKEEKSV VFHEGGIAUGWALEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSPEKKVV VFHEGGIAUGWALKAOPUL ARSDEDAVKLINFFQATERVLAGLEKKTOVLOPEEKKTV VFHEGGIAUGWALKAOPUL ARSDEDAVKLINFFQATERVLAGLEKKTOVLOPEEKKTV VFHEGGIAUGWALKAOPUL ARSDEDAVKLINFFQATERVLAGLEKKTOVLOPEEKKTV VFHEGGIAUGWALKAOPUL ARSDEDAVGAUKHFEQATERVLAGLEKKSLLSPEEKKVV VFHEGGIAUGWALKAOPUL ARSDEDAVGAUKHFEQATERVLAGEKSKLLSPEEKKVV VFHEGGIAUGWALKVOPUL ARGUKRWVSNVEFEKAKDKILMGGERKSVUMTEAGKEST MELGGIAUGWALTONGAPUL KVSIIPRGGGLGYAQULP-REQUITKECLEDRKCMALGGRASEALSFNEVTSGADD KVSIIPRGGGLGYAQULP-PEQUITEREOFARINGMALGGRVEELIFFFSVTSGADD KVSIIPRGGALGYAQULP-PEQUITEREOFARINGMALGGRVEELIFFFSVTSGADD KVSIIPRGGALGYAQULP-PEQUITEREOFARINGMALGGRVEELIFFF-SOLOCMMMARA KVSIIPRGAL-LCVFFFLEEGDAISASRQKLSSJSTLYGGRLAELIYGENVYSTGASD KVSIIPRGVELLIVENTVELTEREDAKINGTRAGLAGUVMUKGGRAUELIFFF-SOLOCMMMARA DIKKVORALAMVSKOFG APEIGF ISFPEADEGLMGIGRRPFSOGLOCMMMARA DIKKVORALAMVSKOFG APEIGF ISFPEADEGNKVSNKPSSNKARTITILLSKS KVSIIPRGALAUKVOFG APEIGF ISFDELPROSULSTARTITILSKOK DIKKVORALAMVYSKOFG APEIGF ISFDELPROSULSTARTITILSKOK	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YHE1L YME1 EColiFtsH Paraplegin AFG3L2 Ytal0 Ytal2 Ytal1 YHE1L YME1L Paraplegin AFG3L2 Ytal0 Ytal2 YHE1L YME1L Paraplegin AFG3L2 Ytal0 Ytal1 Paraplegin	SI 54% 62% 63% 44% 43%	OME Procession ARGENTSVHTLNFETAVERVLAGTAKKSKILSKEGOKVULPEKSILVOMLENTEAVM ARGENTSVHTLNFETAVERVLAGTAKKSKILSKEGOKVULPEKSILVOMLENTEAVM ARKINDPYTTIHHFEQATERVLAGTAKKSKILSKEEKSVULPEKSILVOMLEAGTAVCGWLEHAPPLL ARKINDPYTTIHHFEQATERVLAGTEKKTOVLOPEKKIVAN HEAGTAVCGWLEHAPPLL ARKINDPYTTIHHFEQATERVLAGTEKKTOVLOPEKKIVAN HEAGTAVCGWLEHAPPLL ARKINDPYTTIHHFEQATERVLAGTEKKTOVLOPEKKIVAN HEAGTAVCGWLEHAPPLL ARSDEDAVKLINHFEQATERVLAGTEKKTOVLOPEKKIVAN HEAGTAVCGWLEHAPPLL ARSDEDAVKLINHFEQATERVLAGTEKKSVLISPEKKIVAN HEAGTAVCGWLENAPPLL ARSDEDAVKLINHFEQATERVLAGTEKSVLISPEKKIVAN HEAGTAVCGWLENAPPLL ARSDEDAVKLINHFEQATERVLAGTEKSVLISPEKKIVAN HEAGTAVCGWLENAPPLL ARSDEDAVKLINHFEQATERVLAGTEKSVLISPEKKINAN OCKNAUSVONSHFEKAKADKILMGGERKSVLISPEKKINAN VONNSHFEKAKADKILMGERKSVLISPEKTAN KVSTIPRGQALGYAQYLP-PODYLISEOFRHININLGGRVSEELHFP-SVTSGADD KVSTIPRGQALGYAQYLP-BODYLISEOFRHININLGGRVSEELHFP-SVTSGADD KVSTIPRGQALGYAQYLP-BODYLISEOFRHININLGGRVSEELHFP-SVTSGADD KVSTIPRGQALGYAQYLP-BODYLISEOFRHININLGGRVSEELHFP-SVTSGADD KVSTIPRGQALGYAQYLP-BODYLISEOFRHININLGGRVSEELHFFOSOLOGNMMHARL DIKKVERTAVSMVKOFG APGTOFISFERTAQLLAQUVSMGGRVAELHFFOSOLOGNMMHARL DIKKVERTAVSMVKOFG APGTOFISFERTAQLLAQUVSMGGRVAELHFFOSOLOGNMMHARL DIKKVERTAVSMVKOFG APGTOFISFERTAQLLAQUVSMGGRVAELHFFOSOLOGNMMHARL DIKKVERTAVSMVKOFG APGTOFISFERTAQLISAUVSMGRVAELKAN	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1 ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L YME1L Paraplegin AFG3L2 Yta10 Yta12 Yta10 Yta12 YME1L Paraplegin AFG3L2 Yta10 Yta10 Yta10 Yta10 Yta12 Yta10 Yta	SI 54% 62% 63% 44% 43%	COTO Procession AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEDKVV, FHEGGIAUGWALEHTEAVM ARHLESDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVV, FHEGGIAUGWALEHTEAVM ARHLESDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVV, MEAGIAUGWALEHTEAVM ARHLESDSINOKHFEQAIERVLAGTAKKSKILSKEEKKVV, MEAGIAUGWALKAPPLL ARNDEYTITHHFEQAIERVLAGGEKKTOVLOPEEKKTV, MEAGIAUGWALKAPPLL ARSDEDAVKLINFEQAIERVLAGGEKKTOVLOPEEKKTV, MEAGIAUGWALKAPPLL ARSDEDAVKLINFEQAIERVLAGGEKKTOVLOPEEKKTV, MEAGIAUGWALKAPPLL ARSDEDAVKUNFEGAIERVLGEKKVU, MEAGIAUGWALKAPPLL ARSDEDAVKUNFEGAIERSVLGEKKSKLISPEEKKVV, MEAGIAUGWALKAPPLL ARSDEDAVKUNFEGAIERVLGEKKVVV, MEAGIAUGWALKAPPLL ARGUKRVVKSHFEKAKSKI HMEGGERKSVLJDARKATTHEAGIAIIGKLVPEHPVH	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH	SI 54% 62% 63% 44% 43%	COTO Protection AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UF HESGIAVGWYLEHTAVM ARAKHTSDSINOKHPEGATERVLAGTAKKSKILSKEDGVV UF HESGIAVGWYLEHTAVM ARKHNDPYTTIHHFEQATERVLAGTAKKSKILSKEEKRSV VFHEAGIAVGWYLEHTAPM ARKHNDPYTTIHHFEQATERVLAGTAKKSKILSKEEKRSV VFHEAGIAVGWYLEHTAPM ARKNDPYTTIHHFEQATERVLAGTEKKTOVLOPEEKKYV VFHEAGIAVGWYLEHTAPDLI ARSDEDAVKLINHEQATERVLAGTEKKTOVLOPEEKKYV VFHEAGIAVGWYLEHTAPDLI ARSDEDAVKLINHEGATERVLAGTEKKSKILSPEEKKVV VFHEAGIAVGWYLENAPPLI AND STATUTTISTICUTUR OCKNAVSVONSHFEKAKANEN LINGGERKSVEIDNKIKTIT MESGIATIAVYTKDAMPIN ARGNKRVVSMVEFEKAKDKILMGGERKSMVHTEAQLKST VFHEAGIATIANKSTOATPLY ARGNKRVVSMVEFEKAKDKILMGGERKSMVHTEAQLKST VHEAGIAVGWYLEHTPSVTSGADD KVSTIPROGGALGYAQYLP-POPULIEKEQLENKMINALGGRVSEELHFFSVTSGADD KVSTIPROGGALGYAQYLP-POPULIEKEQLENKMINALGGRVSEELHFFSVTSGADD KVSTIPROGGALGYAQYLP-POPULIEKEQARLDVCMGGKIAELIIFGDEHTGASS KATILPROGRALGITOP APOLIF SFEEGACHLORMSMGGRVEELHFFSVTSGADD KVSTIPROGGALGYAQYLP-POPULIEKEQOTSUGOROMOMERALIIFGDONTSGCGS VSTIPROGGALGYAQYLP-GOTIFIKEQLEPROGUNDSMGGRVEELHFFOSOLGOC MDHARL DIKKURTAYSMVKOFG APOLF SFEEGACHLORMSMGGRVEELHFFOSOLGOC MDHARL DIKKURTAYSMVKOFG APOLF SFEEGACHLORMSMGRVEELIFFONITIGASS SATTUPROGUNDATING SEXIL VISUONANANDANDANDANDANDANDANDANDANDANDANDANDA	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L YHE1L ECOLIFTSH Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 Yta10 Yta12 Yta10 Yta12 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L	SI 54% 62% 63% 44% 43%	OPE Procession ARGHTSVHTLNFETAVERVLAGTAKKSKLISKEDRVV IF HEGGIAVGWILEHTEAVM ARHLSDSINGKHFEGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILEHTEAVM ARHLSDSINGKHFEGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILEHTEAVM ARHLSDSINGKHFEGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILEHTEAVM ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTEAVM ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTAPUL ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTAPUL ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTAPUL ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTAPUL ARSDEDAVGLINEFGAIERVLGGLEKKTOVLOPEEKKIV NHEAGIAVGWILENTAPUL ARSDEDAVGLEFSKÖKLINGGERKSVLIPPUL CONNASVONSHFEWARDKILMGERRSVNTELGARGKESTUPEGALAUNTTSGGAAUGUNUKSTING KVSITPRTNAALGFAQMLP-RDOHLFYKEQLFERMCMALGGRASEALSFNEVTSGADD KVSITPRGGGLGLAQUPP-PDQILTSEOFARININALGGRVSEELHFPSVTSGADD KVSITPRGGALGLAQUP-PODULTSEOFARININALGGRVSEELHFPSVTSGADD KVSITPRGGALGLAQUP-PODULTSEOGANDMERTAGLUOUMGKIAEELIFGCDHINTSGCGS KVSITPRGGALGLAQUP-EDUTIKECLARDVCMGKALEELITGENHATSGCGS KVSITPRGGALGVAQVLP-EDUTIKECLARDVCMGKALEELITGENHATSGCGS KVSITPRGGALGVAQVLP-EDUTIKECLARDVCMGKALEELITGENHALTIGGSS KVSITPRGGALGVAQVLP-EDUTIKECLARDVCMGKALEELITGENHATSGCS KVSITPRGGALGVAQVTPLEGANGTERVELSENTSONGONALAEELITGENTSGLOOKMMHARD DEKKVORAAAD	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 Paraplegin AFG3L2 Ytal0 Ytal2 YME1L YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH Paraplegin AFG3L2 Ytal0 Ytal2 YME1 ECOLIFTSH	SI 54% 62% 63% 44% 43%	COTO Procession ARGENTSVHTLNFETAVERVLAGTAKKSKLISKEDRVV. IV HENGEN UVMLEHTEAVM ARHLESDSINGKHFEGAIERVLAGTAKKSKLISKEDRVV. IV HENGEN AVGWYLEHADPLEI ARHLESDSINGKHFEGAIERVLAGLEKKTOVLOPEEKKT V. YHEAGH AVAGWYLEHADPLEI ARHNOPYTITIHHEGAIEVULAGLEKKTOVLOPEEKKT V. YHEAGH AVAGWYLEHADPLEI ARSDEDAVGULAKTAVESKLISPEEKKSV. VIELAGIAVGGWLEXADPLEI ARSDEDAVGULAKTAVESKLISPEEKKSV. VIELAGIAVGGWLEXADPLEI ARSDEDAVGULAKTINFEGAIERVLIGGEKKSVLISPEEKKSV. VIELAGIAVGGWLEXADPLEI ARSDEDAVGULAVGULAKTAVESKLISPEEKKSV. VIELAGIAVGGWLEXADPLEI ARSDEDAVGULAKTINFEGAIERVLIGGEKSKSLISPEEKKVV. YHEAGHAIGAVGGWLEXADPLEI ARSDEDAVGULAVGULAVGULAVGULAVGULAVGULAVGULAVGUL	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L YHE1 ECOLIFTSH Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L ECOLIFTSH Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L YHE1L YHE1L Paraplegin AFG3L2 Yta10 Yta10 Yta12 YHE1L	SI 54% 62% 63% 44% 43%	COTO Procession AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEDRVVL MENESGALVGWLEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSKEEDRVVL MENESGALVGWLEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSKEEDRVV MENESGALVGWLEHTEAVM ARHLSDSINOKHFEQATERVLAGTAKKSKILSPEEKKSV MENESGALVGWLEKTAPUL ARSDEDAVGLEKVLAGTAKKSKILSPEEKKSV MENESGALVGWLEKTAPUL ARSDEDAVGLEKVLAGTAKKSKILSPEEKKSV MENESGALVGWLEKTAPUL ARSDEDAVGLEFSKDKILMGGERKSVLISPEEKKSV MENESGALVGWLEKTAPUL ARSDEDAVGTUREKSKILSPEEKKSV MENESGALVGWLEKTAPUL ARGUKRWVSNVEFEKAKDKILMGGERKSVLIDARKATERHEAGIA ALGUKVERUPUL	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L YME1L Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1E ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 Yta10 Yta12 YME1L YME1E ECOliFtsH Paraplegin AFG3L2 YE1L YME1E Paraplegin	SI 54% 62% 63% 44% 43%	COME Procession ARGENTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UN FINSGIALVGWILENTEAVM ARKINDPYTTINHFEQATERVLAGTAKKSKILSKEEKRSV UN FINSGIALVGWILENTEAVM ARKINDPYTTINHFEQATERVLAGTAKKSKILSKEEKRSV UN FINSGIALVGWILENTEAVM ARKINDPYTTINHFEQATERVLAGTEKKTOVLOPEEKKTV.NFINEGIAVGWILENTEAVDIL ARKINDPYTTINHFEQATERVLAGTEKKTOVLOPEEKKTV.NFINEGIAVGWILENTEADPLIA ARSDEDAVKLINHFEQATERVLAGTEKKTOVLOPEEKKTV.NFINEGIAVGWILENTEADPLIA ARSDEDAVKLINHFEQATERVLAGTEKKSVLLSPEEKKV.NFINEGIAVGWILKXAPPLIA ARSDEDAVKLINHFEQATERVLAGTEKSVLLSPEEKKV.NFINEGIAVGWILKXAPPLIA ARSDEDAVKLINHFEQATERVLAGTEKSVLLSPEEKKV.NFINEGIAVGWILKXAPPLIA ARSDEDAVKLINHFEQATERVLAGTEKSVLLSPEEKKV.NFINEGIAVGWISTINTKAPPLIA ARGNERVVSMVEFEKAKDKILMGEERKSVLLSPETAKENVLTDAARKAFTY FINEGALAINKSTYTKAPPLIA VCURNAVSVMSHEYEKAKDKILMGEERKSVLTPKEOLERMCMLEGGASEALSFNEVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRSEELIFFFSVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRVSEELIFFFSVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRVSEELIFFF-SVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRVSEELIFFF-SVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRVSEELIFFF-SVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGRVSEELIFFF-SVTSGADD KVSTIPROGGALGYAQYLP-EDQULIFKEOLFRENCHLEGGVUSKGKILFFFENCHTGASS KVSTIPROGGALGYAQYLP-EDQULIFKEOLFNALGYNKSKGUSTALIFFFONTEGGNS KVSTIP	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YKE1L YKE1L YKE1L Paraplegin AFG3L2 Yta10 Yta12 YKE1L Paraplegin AFG3L2 Yta10 Yta12 YKE1L YKE1L YKE1L YKE1L Paraplegin AFG3L2 Yta10 Yta12 YKE1L YKE1L Paraplegin AFG3L2 Yta10 Yta12 YKE1L	SI 54% 62% 63% 44% 43%	COTO Protesting AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEEDRVV IF HEGGIAVGWILEHTEAVM ARHLESDSINOKHFEQAIERVLAGTAKKSKILSKEEDRVV IF HEGGIAVGWILEHTEAVM ARHLESDSINOKHFEQAIERVLAGLEKKTOVLOPEEKKTV IF HEGGIAVGWILEHTEAVM ARHLESDSINOKHFEQAIERVLAGLEKKTOVLOPEEKKTV IF HEGGIAVGWILEHTEAVM ARSDEDAVKINHFEQAIERVLAGLEKKTOVLOPEEKKTV IF HEGGIAVGWILEHTEAVM ARSDEDAVKINHFEQAIERVLAGLEKKTOVLOPEEKKTV IF HEGGIAVGWILENAOPLI ARSDEDAVKINHFEQAIERVLAGUERKSVLOPEEKKTV IF HEGGIAVGWILENAOPLI ARSDEDAVKINHFEQAIERVLAGUERKSVLOPEKKTV IF HEGGIAVGWILENAOPLI ARGURRWVSNVEFEKAKDKILMGEERKSVLOUKKKITT MIESGIAILSVTKOAPPIN CYNNIPRGKELGYAQYLP-REQUIERKENVETAARKSTN HEGGIAIGKSEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGGLEGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGALGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD KVSSIIPRGGALGYAQYLP-PEQUIEREGOFHRINALGGRVEELIFFO-SVTSGADD DIKKWURAALGINGENKURKENEDATALUSKEONTSGGS KVSSIIPRGGALGYAQYLP-GOFHILKEQOINDWERGALDVCMGKIAELI IGDENTYSGASD KYSSIIPRGGGLEGYAQYLP-GOFHILKEQOINDWERGRVEELIFFO-SVTSGADD	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1L YME1L Paraplegin AFG3L2 Yta10 Yta12 YME1L YME1E ECOliFtsH Paraplegin AFG3L2 Yta10 Yta12 Yta10 Yta12 YME1L YME1E ECOliFtsH Paraplegin AFG3L2 YE1L YME1E Paraplegin	SI 54% 62% 63% 44% 43%	COTO Protection AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UF HESGIAUGWHLEHTEAVM ARAEGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UF HESGIAUGWHLEHTEAVM ARHNDPYTTHHFEQATERVLAGTAKKSKILSKEDGVV UF HEAGIAVGWHLEHTEAVM ARNDDPYTTHHFEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAPUL AND GKEMVTMKELEFSKDKILMGGERKSVLIDGKKKTITTHESGIAILSTYTKDAPPIL AND GKEMVTMKELEFSKDKILMGGERKSVLIDKKKTITTHESGIAILSTYTKDAPPIL AND GKEMVTMKELEFSKDKILMGGERKSVLIDKKKTITTHESGIAILSTYTKDAPPIL CONNAVSUMSHFEKAKADKILMGGERKSVLIDFRICKALGGRASEALSFNEVTSGADD KVSIIPRGQGALGYAQYLP-POPULISEQOFNIRMIMALGGRVSEELHFPSVTSGADD KVSIIPRGQGALGYAQYLP-POPULISEQOFNIRMIMALGGRVSEELHFPSVTSGADD KVSIIPRGQGALGYAQYLP-GDIFLILTEQQLUDRIKMISLGRVSEELHFPSVTSGADD KVSIIPRGQGALGYAQYLP-GDIFLISFEQALEQUVCHGKIAELIJGEDMUTTGGSS KATILPRGRA-LGITTOLPENDAKNETSQEGSDMULGGRVSETIFFOOLOOMHTAGL SUMMURAALGUTYCG APGID ISFFEAGESDMUL-SKIISTATATILD VKS KATILPRGRA-LGITTOLPENDAVISAGRVSELTYPENDETGILID VKS DFKNVINANATAVTSLG SEKLGVINGSENGEVELKEVENDETOGULOGRMATATIGSS SUMUTARANDVENAVENDEVEKVINGENGELISETTIDUAKS SUMUTARANDVENAVENDEVEKKENDETOGILDUAKAN <td>Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues</td>	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YKE1L YKE1L YKE1L ECOLIFTSH Paraplegin AFG3L2 Yta10 Yta12 YKE1L ECOLIFTSH Paraplegin AFG3L2 Yta10 Yta12 YKE1L YKE1	SI 54% 62% 63% 44% 43%	COTO Protection AREGHTSVHTLNFETAVERVLAGTAKKSKLISKEDGVVULFHEGGLAVGWHLEHTEAVM ARHLESDSINGKHFEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLEHADPLL ARHNDFYTTTHHFEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLEHADPLL ARNNDFYTTHHFEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLKADPLL ARSDEDAVGLMETEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLKADPLL ARSDEDAVGLMETEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLKADPLL ARSDEDAVGLMETEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLKADPLL ARSDEDAVGLMETEGATERVLGGLEKKTOVLOPEEKKTVNFHEAGHAVGWYLKADPLL ARSDEDAVGLEFSKDVLIMEGGLEKKTWVLTDARKATTFHEAGHAVGWGWLKADFUNG ARGURRWVSKUEFEKAKDVLIMEGERKSVUPTEAGKESTPYHEAGHALGUNGGWLAUGTUNGGTAUGUNUTTGGTGA KVSITPRTNAALGFAQMLP-RDOHLFTKEQLFERMCMALGGRASEALSFNEVTSGADD KVSITPRGGGLEGAQULP-PODULTEEOGLERMUMTEGGREVEELHFPSVTSGADD KVSITPRGGGLEGAQULP-PODULTEEOGLERMUMTEGGRAUEGUNUTTSGCGS KVSITPRGGALGAGYQLP-PODULTEEOGLERMUMTEGGRAUEGUNUTTSGCGS KVSITPRGGALGAGYQLP-GENFLETEDGLENGTUNGKALEELIYGDHNTSGCGS KVSITPRGGALGUNQUND-EDEMKVUTTRKECGARLDVUNGGKLAEELIYGDHNTSGCGG KVSITPRGGALGUNQUND-EDEMKVUTTRKECGARLDVUNGGKLAEELIYGDHNTSGCGG KVSITPRGGALGUNQUNCGAPGITETSFDEGODMULSERNES SATTERTTGGND DIKKVUTSKANDVERGAADITETSECGE DIKKVUTSKANDVERGGAADITETSECGE DIKKVUTSKANDVERGGAADITETSECGE DIKKVUTSKANDVERGGAADITETSECGE DIKK	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues
Paraplegin AFG3L2 Yta10 Yta12 YHE1L YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin AFG3L2 Yta10 Yta12 YHE1L Paraplegin	SI 54% 62% 63% 44% 43%	COTO Protection AREGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UF HESGIAUGWHLEHTEAVM ARAEGHTSVHTLNFETAVERVLAGTAKKSKILSKEDGVV UF HESGIAUGWHLEHTEAVM ARHNDPYTTHHFEQATERVLAGTAKKSKILSKEDGVV UF HEAGIAVGWHLEHTEAVM ARNDDPYTTHHFEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAVM ARSDEDAVKLINHTEQATERVLAGTEKKTOVLOPEEKKTVA HEAGIAVGWHLEHTEAPUL AND GKEMVTMKELEFSKDKILMGGERKSVLIDGKKKTITTHESGIAILSTYTKDAPPIL AND GKEMVTMKELEFSKDKILMGGERKSVLIDKKKTITTHESGIAILSTYTKDAPPIL AND GKEMVTMKELEFSKDKILMGGERKSVLIDKKKTITTHESGIAILSTYTKDAPPIL CONNAVSUMSHFEKAKADKILMGGERKSVLIDFROMUTDAKATATHEAGIAILGRUVEELHFP KVSTIPRGQGALGYAQYLP-POPULISEQOFAHRMIMALGGRVSEELHFPSVTSGADD KVSTIPRGQGALGYAQYLP-POPULISEQOFAHRMIMALGGRVSEELHFPSVTSGADD KVSTIPRGQGALGYAQYLP-POPULISEQOFAHRMIMALGGRVSEELHFPSVTSGADD KVSTIPRGQGALGYAQYLP-GDIFILTEQQLUDRMTMSLGGRVSEELHFPSVTSGADD KVSTIPRGQGALGYAQYLP-GDIFILTEQQLUDRMTMSLGGRVSEELHFPSVTSGADD KVSTIPRGQGALGYAQYLP-GAPGIFISFEQALGODMULGGRVSETAFICADS KVSTIPRGQGALGYAQYLP-GAPGIFISFEQALGODMULGGRVSETAFICADS KVSTIPRGQGALGYAQYLP-GAPGIFISFEQALGONFKV-NKPSNKTAFILDVKSGS KYTTIPRGQGALGYAQYLP-GAPGIFISFEQALGONFKV-NKPSNKTAFILDVKSGV KYSTIPRGQGALGYAQY	Putative substrate interacting residues Glycine linker Protease active site Zinc coordinating residues

Figure S3. Sequence analysis of the FtsH-related protein family._Related to Figures 2, 3, 4, 5 and 6.

ClustalW alignment of the sequences of **A**. ATPase and **B**. protease domains of human AFG3L2 and diverse members of FtsH-related proteins: human paraplegin, *S. cerevisiae* Yta10 and Yta12, human and *S. cerevisiae* YME1L and YME1, and *E. coli* FtsH. Overall sequence identity of the catalytic core of each homolog to AFG3L2 is shown in %. Asterisk denotes strict conservation across all homologs, and one or two dots indicate high sequence similarity. All elements important for the mechanism of ATP hydrolysis, substrate translocation, and proteolytic cleavage are strictly conserved and labeled in the legend. Disease-related residues in AFG3L2 are highlighted in red and non-conserved regions of the catalytic core are delineated by boxes, colored as follows: N-terminus (blue), pore-loop 2 (green), central protease loop (purple), and C-terminus (red).




Figure S4. The effects of diverse mutations on AFG3L2 hexameric stability and ATP binding/hydrolysis *in vitro*. Related to Figures 2, 3, 4, 5, and 6.

Size exclusion chromatography (SEC) analysis of the ^{core}AFG3L2^{WB/PI} construct upon incorporation of **A**. Truncations in the N- and C-termini, **B**. The ATPase disease-related substitutions with the ATP binding incompetent Walker A (WA, K354A) as a control, **C**. The mutations of the central protrusion associated with disease, **D**. The disease-related substitutions of the lateral interface in between adjacent protease domains, and **E**. The recessive disease-linked substitutions involved in proteolytic cleavage. In each case, the ^{core}AFG3L2^{WB/PI} construct was used as a control and the loss of the hexameric peak and increase in the disassembled peak indicate reduced stability of the affected constructs. **F**. Rate of ATP hydrolysis against ATP concentration for ^{cchex}AFG3L2 and its variant with N432T substitution. Data were fit to the Hill version of the Michaelis–Menten equation (For WT: $k_{\text{ATPase}} = 92.6 \text{ min}^{-1} \text{ enz}_6^{-1}$; $K_{0.5} = 45 \mu$ M; For N432T: $k_{\text{ATPase}} = 22.4 \text{ min}^{-1} \text{ enz}_6^{-1}$; $K_{0.5} = 5.6 \mu$ M). Values are means of independent replicates (n ≥ 3) ± SD.3




Figure S5. Structural details of the protease active site. Related to Figure 6.

A. Side view of the proteolytic site shows that the disease-related residue A572 (highlighted in green) inserts into a hydrophobic pocket formed by residues Y573, I596, L730 and L731, all of which are shown in blue. **B.** Top view of the proteolytic site shows that the P1' residue (pink) of the substrate faces a hydrophobic pocket (green) formed by residues V571, L603, G645 of the *cis* subunit, and L615 from the adjacent subunit. The substrate density extends in between Y614 and the disease-associated Y616 from the neighboring subunit.

Mutation	Hexamerization <i>in vitro</i> (SEC results)	ATP	Substrate degradation	Mechanism	Disease	Inheritance (Autosomal)	Age of onset (ave, range, # of patients)	Ref.	Clinical character	istics
R468C	-	-	-	Blocks ATP binding	DOA	Dominant	9, 6-12, n=2	1,2	Dominant negative; Visual difficulties (color vi	sion impairment and photophobia)
N432T	+++	-	-	Blocks ATP hydrolysis	SCA28	Dominant	Not reported	3	Canonical SCA28; Dominant negative	
S674L	-	+	-	Protease destabilization	SCA28	Dominant	Not reported	3	Canonical SCA28	
P688T	+	++	++	Protease destabilization	SCA28	Dominant	31, 31, n=1	4	Canonical SCA28; Mildest phenotype in patie	ents
Y689N	-	-	-	Protease destabilization	SCA28	Dominant	32, 16-55, n=3	5	Canonical SCA28	
Y689H	-	-	+	Protease destabilization	SCA28	Dominant	43, 43, n=1	6	Canonical SCA28	
E691K	-	-	-	Protease destabilization	SCA28	Dominant	Not reported	3	Canonical SCA28; Dominant negative	
A694E	-	+	+	Protease destabilization	SCA28	Dominant	Not reported	3	Canonical SCA28	
G671R	-	+	+	Protease destabilization	SCA28	Dominant	28, 14-53, n=16	7,8	Canonical SCA28	
G671E	-	-	-	Protease destabilization	SCA28	Dominant	55, 55, n=1	7	Canonical SCA28	
M666R	-	-	-	Protease destabilization	SCA28	Dominant	7, 6-8, n=2	7	Canonical SCA28; Early onset, severe diseas	se
M666V	-	-	-	Protease destabilization	SCA28	Dominant	31, 14-50, n=6	7	Canonical SCA28	
M666T	-	-	+	Protease destabilization	SCA28	Dominant	20, 20, n=1	7	Canonical SCA28	
A572T	+++	+++	++	Reduced proteolysis	Unnamed	Recessive	7 mo, 6-8 mo, n=5	9	Regression of developmental milestones, mic	crocephaly, epilepsy, failure to thrive
Y616C	+++	+++	+++	Increased proteolysis	SPAX5	Recessive	2, 2, n=1	10	Canonical SPAX	
T654I	-	-	-	Protease destabilization	SCA28	Dominant	30, 10-60, n=3	7	Canonical SCA28	
E700K	-	-	-	Protease destabilization	SCA28	Dominant	10, 3-28, n=5	11	Canonical SCA28; Early onset, severe diseas	se
R702Q	-	-	+	Protease destabilization	SCA28	Dominant	Not reported	3	Canonical SCA28	
	Legend - + ++	0-25 25-5 50-7	0%	Canonical SCA28	clinical d	characteris	tics dysarth nysta	nria, agm	pressive gait and limb ataxia, hyperreflexia at lower limbs, us and ophthalmoparesis remity spasticity, peripheral	References 1. Colavito et al., 2017 2. Charif et al., 2015 3. Di Bella et al., 2010 4. Svenstrup et al. 2017 5. Zuhlke et al. 2015 6. Lobbe et al. 2013
	+++	>75	%	Canonical SPAX	clinical c	haracteris	dyst	onia	, ptosis, oculomotor apraxia, a, cerebellar atrophy, and ssive myoclonic epilepsy	7. Cagnoli et al. 2010 8. Szpisjak et al. 2017 9. Eskandrani et al. 2017 10. Pierson et al. 2011 11. Edener et al. 2010

Table S1. Biochemical characterization and reported clinical phenotypes linked to disease-related substitutions in AFG3L2. Related to Figure 2,4,5 and 6. For each mutation characterized in this study, we show the hexamerization, ATP hydrolysis and substrate degradation rates we determined *in vitro*, as well as our proposed mechanism. We also summarize and reference the clinical characteristics and inheritance patterns previously reported in each case.

Table S2. Cryo-EM data collection, refinement, and validation statistics. Related to STAR Methods.

	^{core} AFG3L2 ^{WB/PI}			
	PDB ID: 6NYY EMDB ID: 0552			
Data collection and Processing				
Microscope	Talos Arctica			
Camera	Gatan K2 Summit			
Magnification	36,000			
Voltage (kV)	200			
Total electron exposure $(e^{-}/Å^2)$	40			
Exposure rate (e-/pixel/sec)	4.3			
Defocus range (µm)	0.8 to 1.8			
Pixel size (Å)	1.15			
Acquisition software	Leginon (Suloway et a	al., 2005)		
Exposure navigation	Image shift			
Micrographs collected (no.)	5,707			
Micrographs used (no.)	5,378			
Total extracted particles (no.)	4,541,491			
Refined particles (no.)	2,901,805			
Final particles (no.)	1,129,437			
Accuracy of Rotations/Translations	1.09/0.41			
Symmetry	C1			
Resolution (global, Å)				
FSC 0.5 (unmasked/masked)		ATPase A, F: 10.1/7.1	Protease: 3.6/3.2	
FSC 0.143 (unmasked/masked)	ATPase B-E: 3.2/3.0	ATPase A, F: 7.5/5.2	Protease: 3.3/2.9	
Resolution Range (local, Å)	2.7 - 10			
Map sharpening <i>B</i> factor (Å ²)	ATPase B-E: -111	ATPase A, F: -155	Protease: -93	
Model composition*				
Nonhydrogen atoms	18704			
Protein residues	2396			
Ligands	12			
B C (
Refinement		0010		
Refinement package	Phenix (Afonine et al.	, 2012)		
MapCC (global/local)	0.84/0.85			
<i>B</i> factors (Å ²)	04.0			
Nonhydrogen atoms	84.6			
Protein residues	84.6			
Ligands	75.3			
R.m.s. deviations	0.006			
Bond lengths (Å)	0.006			
Bond angles (°)	0.799			
Validation				
MolProbity score	1.58			
Clashscore	3.93			
Poor rotamers (%)	0.05			
C-beta deviations				
Ramachandran plot				
Favored (%)	94.06			
Allowed (%)	5.94			
Disallowed (%)	0.00			
Mean per-residue Cα RMSD (Å)	0.51			
Per-residue Cα RMSD range (Å)	0.02-4.57			
CaBLAM outliers (%)	2.5			
EMRinger score (Barad et al., 2015)	3.4			

*Atomic statistics and validation do not include the ATPase domains of subunits A & F

Table S3. Oligonucleotides used in this study. Related to STAR Methods.

Table S3. Oligonucleotides used in this study. Related to STAR	Methous.	
OLIGONUCLEOTIDES	SOURCE	IDENTIFIER
AFG3L2 ²⁷²⁻⁷⁹⁷ (Forward): 5'-tacttccaatccaatgcaagaagagggcctgctggc-3'	Ding et al., 2018	PMID: 29932645
AFG3L2 ²⁷²⁻⁷⁹⁷ (Reverse): 5'-ttatccacttccaatgttattagttggcaactttctcacc-3'		
AFG3L2 ^{Δ272-281} (Forward): 5'-tacttccaatccaatgcaggccgagggatgggccgac-3'	This Study	N/A
AFG3L2 ^{Δ272-295} (Forward): 5'-tacttccaatccaatgcagccaaggtcttaaaggatg-3'	This Study	N/A
AFG3L2 ^{Δ781-797} (Reverse): 5'-ttatccacttccaatgttattagttccagtccttaaggccttc-3'	This Study	N/A
AFG3L2 ^{Δ750-797} (Reverse): 5'-ttatccacttccaatgttattatggtctggggcccaaaag-3'	This Study	N/A
AFG3L2 ^{WB} (Top): 5'-cagatcgatgcggtgggaaggaagaggag-3'	Ding et al., 2018	PMID: 29932645
AFG3L2 ^{WD} (Bottom): 5'-atcgatgaagaggatgcaaggggcattcttccg-3'		
AEG3L2 ^{PL} (Top): 5'-caggcaggccatgcggttgcc-3'	Ding et al., 2018	PMID: 29932645
AFG3L2 ^{PI} (Bottom): 5'-gtggtatgccacagtcttcttctcctc-3'		
AFG3L2 ^{WA} (Top): 5'-gcgacgctgctagctaaggccacag-3'	This Study	N/A
AFG3L2 ^{WA} (Bottom): 5'-cccagtgcctggaggaccagtgag-3'		
AFG3L2 ^{F289A} (Top): 5'-gccagtgtcggagaaaccac-3'	This Study	N/A
AFG3L2 ^{F209A} (Bottom): 5'-gagtccgcccatccctcg-3'		
AFG3L2 ^{L299A} (Top): 5'-gcaaaggatgaaattgatgtgaagttcaaag-3'	This Study	N/A
AFG3L2 ^{L299A} (Bottom): 5'-gaccttggcagtggtttctcc-3'		
AFG3L2 ^{M380V} (Top): 5'-gtgttcgttggtgtgggccc-3'	This Study	N/A
AFG3L2 ^{M380V} (Bottom): 5'-ctccaaaaactcagatccactaacggt-3'		
AFG3L2 ^{M380K} (Top): 5'-agttcgttggtgtgggccc-3'	This Study	N/A
AFG3L2 ^{M380K} (Bottom): 5'-tctccaaaaactcagatccactaacgg-3'		
AFG3L2 ^{F381A} (Top): 5'-cgttggtgtgggccctg-3'	This Study	N/A
AFG3L2 ^{F381A} (Bottom): 5'-gccatctccaaaaactcagatccac-3'		
AFG3L2 ^{F421A} (Top): 5'-gctggagggcagagtgagc-3'	This Study	N/A
AFG3L2 ^{F421A} (Bottom): 5'-gttgcctcttccttccttcc-3'	This Otudu	N1/A
AFG3L2 ^{N432T} (Top): 5'-acccagctgctggtggagatggatgg-3' AFG3L2 ^{N432T} (Bottom): 5'-gagtgtgttctccctgctcactctgcc-3'	This Study	N/A
	This Study	N/A
AFG3L2 ^{R468C} (Top): 5'-tgtttcgacaggcagatctttattggac-3' AFG3L2 ^{R468C} (Bottom): 5'-ccccggcctaagtagcgcg-3'		IN/A
A F70T	This Study	N/A
AFG3L2 ^{A572T} (Top): 5'-taccacgaagcaggccatg-3' AFG3L2 ^{A572T} (Bottom): 5'-ggtcacagtcttcttctcctcaggc-3'		IN/A
AFG3L2 ^{A572T/PI} (Top): 5'-taccaccaggcaggcc-3'		
AFG3L2 ^{Y616C} (Top): 5'-gtaccaaagagcagctcttgg-3'	This Study	N/A
AFG3L2 ^{Y616C} (Bottom): 5'-agaggtattgttcttttggtaaatactgagc-3'		
AFG3L2 ^{T654I} (Top): 5'-attcagagtgcatatgcccaaattgttc-3'	This Study	N/A
AFG3L2 ^{T6541} (Bottom): 5'-tacttttctcaagtcatcttgagcacc-3'	,	
AFG3L2 ^{M666R} (Top): 5'-cgtaatgaaaaggttgggcaaatctcc-3'	This Study	N/A
AFG3L2 ^{M666V} (Top): 5'-atgaatgaaaaagattgggcaaatctcc-3'		
AFG3L2 ^{M666T} (Top): 5'-accaatgaaaaggttgggcaaatctcc-3'		
AFG3L2 ^{M666} (Bottom): 5'-gccaaactgaacaatttgggcatatgcac-3'		
AFG3L2 ^{G671E} (Top): 5'-gaacaaatctcctttgacctccc-3'	This Study	N/A
AFG3L2 ^{G671R} (Top): 5'-cgtcaaatctcctttgacctccc-3'		
AFG3L2 ^{G671} (Bottom): 5'-aaccttttcattcatgccaaactgaac-3'		
AFG3L2 ^{S674L} (Top): 5'-ctgtttgacctcccacgtcaggg-3'	This Study	N/A
AFG3L2 ^{S674L} (Bottom): 5'-gatttgcccaaccttttcattcatgcc-3'		

AFG3L2 ^{M683A} (Top): 5'-gcggtattggagaaaccttacagtg-3' AFG3L2 ^{M683A} (Bottom): 5'-gtccccctgacgtgggagg-3'	This Study	N/A
AFG3L2 ^{P688T} (Top): 5'-acctacagtgaagccactgcaagattg-3' AFG3L2 ^{P688T} (Bottom): 5'-tttctccaataccatgtccccctgacg-3'	This Study	N/A
AFG3L2 ^{Y689N} (Top): 5'-aacagtgaagccactgcaagattgata-3' AFG3L2 ^{Y689H} (Top): 5'-cacagtgaagccactgcaagattgata-3' AFG3L2 ^{Y689} (Bottom): 5'-aggtttctccaataccatgtcccc-3'	This Study	N/A
AFG3L2 ^{E691K} (Top): 5'-aaagccactgcaagattgatagatgatg-3' AFG3L2 ^{E691K} (Bottom): 5'-actgtaaggtttctccaataccatgtcc-3'	This Study	N/A
AFG3L2 ^{A694E} (Top): 5'-gaaagattgatagatgatgaagtacg-3' AFG3L2 ^{A694E} (Bottom): 5'-agtggcttcactgtaaggtttctcc-3'	This Study	N/A
AFG3L2 ^{E700K} (Top): 5'-aaagtacgaatacttattaatgatgc-3' AFG3L2 ^{E700K} (Bottom): 5'-atcatctatcaatcttgcagtggc-3'	This Study	N/A
AFG3L2 ^{R702Q} (Top): 5'-caaatacttattaatgatgc-3' AFG3L2 ^{R702Q} (Bottom): 5'-tacttcatcatctatcaatcttgc-3'	This Study	N/A
AFG3L2 ^{W779R} (Top): 5'-cggaacaaggagcgggaaaaggag-3' AFG3L2 ^{W779R} (Bottom): 5'-gtccttaaggccttctggaagtgag-3'	This Study	N/A